


FRONTIERS IN MOLECULAR PHARMING



Editor:

Muhammad Sarwar Khan

Bentham Books

Frontiers in Protein and Peptide Sciences

(Volume 2)

Frontiers in Molecular Pharming

Edited by

Muhammad Sarwar Khan

Centre of Agricultural Biochemistry

and Biotechnology (CABB)

University of Agriculture

Faisalabad

Pakistan

Frontiers in Molecular Pharming

Volume # 2

Frontiers in Molecular Pharming

Editor: Muhammad Sarwar Khan

ISSN (Online): 2213-9877

ISSN (Print): 2589-2924

ISBN (Online): 978-981-5036-66-4

ISBN (Print): 978-981-5036-67-1

ISBN (Paperback): 978-981-5036-68-8

© 2021, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

| | |
|---|-----------|
| PREFACE | i |
| LIST OF CONTRIBUTORS | iii |
| SECTION I: SYSTEM BIOLOGY – <i>IN SILICO</i> CHARACTERIZATION OF PROTEINS AND AND PEPTIDES | |
| CHAPTER 1 TOOLS FOR PREDICTION AND VALIDATION OF EPITOPIC REGIONS ON PROTEIN TARGETS FOR VACCINE DEVELOPMENT AND DIAGNOSTICS | 1 |
| <i>Soban Tufail, Majid Ali Shah, Maryam Zafar, Mazhar Iqbal, Amjad Ali Aamir Shehzad and Moazur Rahman</i> | |
| 1. IMMUNE SYSTEM-AN OVERVIEW | 2 |
| 2. IDENTIFICATION OF EPITOPES | 4 |
| 3. TARGET SELECTION FOR EPITOPE PREDICTION | 5 |
| 4. TOOLS FOR PREDICTION OF LINEAR B-CELL EPITOPES | 7 |
| 5. TOOLS FOR PREDICTION OF CONFORMATIONAL B-CELL EPITOPES | 8 |
| 6. PREDICTION OF T-CELL EPITOPES | 9 |
| 6.1. Tools for Prediction of MHC Class I Binding Peptides | 9 |
| 6.2. Tools for Prediction of MHC Class II Binding Peptides | 10 |
| 7. FURTHER CONSIDERATIONS | 10 |
| 8. LIMITATIONS OF EPITOPE PREDICTION TOOLS AND THE WAY FORWARD | 10 |
| 9. VALIDATION OF B- AND T-CELL EPITOPES | 12 |
| 9.1. Tools for Validation of B-cell Epitopes | 13 |
| 9.1.1. Enzyme-Linked Immunosorbent Assay | 14 |
| 9.1.2. Immunoblotting | 14 |
| 9.1.3. Virus Neutralization Test | 15 |
| 9.1.4. Lateral Flow Assay | 16 |
| 9.2. Tools for Validation of T-Cell Epitopes | 16 |
| 9.2.1. Mass spectrometry (MS) | 16 |
| 9.2.2. Enzyme-linked Immune Absorbent Spot (ELISpot) | 16 |
| 9.2.3. Intracellular Cytokine Staining (ICS) Assay | 17 |
| 9.2.4. Tetramer Staining | 17 |
| CONCLUDING REMARKS | 17 |
| CONSENT FOR PUBLICATION | 17 |
| CONFLICT OF INTEREST | 17 |
| ACKNOWLEDGEMENTS | 17 |
| REFERENCES | 18 |
| CHAPTER 2 IMMUNOINFORMATICS AND ITS ROLE IN VACCINE DEVELOPMENT | 30 |
| <i>Iqra Mehmood, Amna Bari, Sajjad Ahmad, Anam Naz, Farah Shahid, Usman Ali, Ashfaq, Kishver Tusleem and Muhammad Tahir ul Qamar</i> | |
| 1. INTRODUCTION | 31 |
| 2. TRANSFORMATION OF VACCINOLOGY FROM CONVENTIONAL TO MODERN ERA | 32 |
| 3. SUBTRACTIVE GENOMICS AND REVERSE VACCINOLOGY | 35 |
| 3.1. Epitope Based Vaccine Design | 39 |
| 3.2. Multiple Epitope Sub-unit Vaccines | 40 |
| 3.3. Antigen Based Vaccine Design | 42 |
| 4. RECENT ADVANCEMENTS IN IMMUNOINFORMATICS | 44 |
| 4.1. B and T Cell Epitope Prediction Tools and Databases | 44 |
| 4.2. Allergens Informatics | 45 |

| | |
|---|-----------|
| 5. IMMUNOINFORMATICS QUEST AGAINST SARS-COV-2 | 49 |
| 6. LIMITATIONS OF IMMUNOINFORMATICS | 50 |
| 7. FUTURE PERSPECTIVE AND CONCLUSIONS | 51 |
| CONSENT FOR PUBLICATION | 51 |
| CONFLICT OF INTEREST | 52 |
| ACKNOWLEDGMENTS | 52 |
| REFERENCES | 52 |
| CHAPTER 3 COMPUTATIONAL TOOLBOX FOR ANALYSIS OF PROTEIN | |
| THERMOSTABILITY | 66 |
| <i>Syed Farhat Ali</i> | |
| 1. INTRODUCTION | 66 |
| 2. BASIS OF PROTEIN THERMOSTABILITY | 67 |
| 2.1. Electrostatic Interactions | 68 |
| 2.2. Hydrogen Bonds | 69 |
| 2.3. Hydrophobic Interaction | 69 |
| 2.4. Disulfide Bonds | 70 |
| 2.5. Protein Rigidity and Flexibility | 70 |
| 2.6. Amino Acid Composition | 70 |
| 3. TOOLS AND APPROACHES FOR <i>IN SILICO</i> ANALYSIS OF PROTEIN | |
| THERMOSTABILITY | 71 |
| 3.1. FireProt | 72 |
| 3.2. ScooP | 72 |
| 3.3. KStable | 72 |
| 3.4. CUPSAT | 73 |
| 3.5. PROTS | 73 |
| 3.6. FoldX | 73 |
| 3.7. RankProt | 73 |
| 3.8. iStable2.0 | 74 |
| 3.9. Rosetta Design | 74 |
| 3.10. Comparative Analysis of Tools for Thermostability Prediction | 74 |
| 4. RELEVANT DATABASES | 75 |
| 5. APPLICATIONS OF <i>IN SILICO</i> APPROACHES FOR PROTEIN | |
| THERMOSTABILITY ANALYSIS AND IMPROVEMENT | 75 |
| CONCLUSION | 77 |
| CONSENT FOR PUBLICATION | 77 |
| CONFLICT OF INTEREST | 77 |
| ACKNOWLEDGMENTS | 77 |
| REFERENCES | 77 |
| CHAPTER 4 PAN-PROTEOMICS TO ANALYZE THE FUNCTIONAL COMPLEXITY OF | |
| ORGANISMS | 81 |
| <i>Muhammad Tahir ul Qamar, Barira Zahid, Fatima Khalid, Anam Naz, Jia-Ming</i> | |
| <i>-Song, Sajjad Ahmad, Xitong Zhu, Feng Xing, Muhammad Sarwar Khan and Ling, Ling Chen</i> | |
| 1. INTRODUCTION | 82 |
| 2. CONCEPT OF PAN-PROTEOMICS | 83 |
| 3. APPROACHES AND SOFTWARE USED FOR PAN-PROTEOMICS | 83 |
| 4. APPLICATIONS AND EXPERIMENTAL DESIGN OF PAN-PROTEOMICS IN | |
| PROKARYOTES RESEARCH | 85 |
| 4.1. Proteome Retrieval and Removal of Duplicate Sequences | 88 |
| 4.2. Searching of essential, non-homologous proteins | 89 |

| | |
|--|-----|
| 4.3. Metabolic pathway analysis | 89 |
| 4.4. Drug-Ability Analysis | 89 |
| 4.5. Prediction of Subcellular Localization | 90 |
| 5. APPLICATION OF PAN-PROTEOMICS IN EUKARYOTES RESEARCH | 90 |
| 5.1. Utilization in Plant's Research | 90 |
| 5.2. Utilization in Animals and Human Research | 91 |
| 5.3. Utilization in Cancer Studies | 92 |
| CONCLUSIONS AND FUTURE PERSPECTIVES | 92 |
| CONSENT FOR PUBLICATION | 93 |
| CONFLICT OF INTEREST | 93 |
| ACKNOWLEDGMENTS: | 93 |
| REFERENCES | 93 |
| CHAPTER 5 FUNCTIONAL CHARACTERIZATION OF PROTEINS AND PEPTIDES USING COMPUTATIONAL APPROACHES | 99 |
| <i>Zeshan Haider and Adnan K. Niazi</i> | |
| 1. INTRODUCTION | 99 |
| 2. IN-SILICO ANALYSIS OF PEPTIDES | 101 |
| 2.1. Classification and Databases of Peptides | 101 |
| 2.2. Algorithm for Prediction of Peptides and their Function | 103 |
| 2.2.1. Search for Similar Fragments | 103 |
| 2.2.2. Search for Evolutionary Conservation | 104 |
| 2.2.3. Search for Statistical Patterns | 104 |
| 2.3. Prediction Features for Prediction of Peptides Model | 104 |
| 2.3.1. Amino Acid Composition | 104 |
| 2.3.2. Atomic Composition of Amino Acids | 105 |
| 2.3.3. Chemical Descriptors | 106 |
| 3. IN-SILICO ANALYSIS OF PROTEINS | 107 |
| 3.1. Protein Databases for Sequence Retrieval | 107 |
| 3.1.1. Organism-specific and Protein Family Based-databases | 108 |
| 3.1.2. Protein Family-Based Databases | 108 |
| 3.1.3. Organism Specified Protein Databases | 108 |
| 3.2. Classification of Protein Sequences | 109 |
| 3.2.1. Methods for Classification of Protein Sequences | 109 |
| 3.2.2. Signatures Databases for Protein | 110 |
| 3.2.3. Super Integrated Signatures Databases for Proteins | 110 |
| 4. MOLECULAR DOCKING-BASED PEPTIDE PREDICTION | 111 |
| CONCLUSION | 112 |
| CONSENT FOR PUBLICATION | 113 |
| CONFLICT OF INTEREST | 113 |
| ACKNOWLEDGEMENTS | 113 |
| REFERENCES | 113 |
| SECTION II: MOLECULAR PHARMING FOR HUMAN BEINGS | |
| CHAPTER 6 MOLECULAR PHARMING: RESEARCH, DEVELOPMENTS AND FUTURE PERSPECTIVE | 119 |
| <i>Muhammad Sarwar Khan, Ghulam Mustafa and Faiz Ahmad Joyia</i> | |
| 1. INTRODUCTION | 119 |
| 2. HISTORY OF THE BIOPHARMACEUTICAL INDUSTRY | 121 |
| 3. VARIOUS PRODUCTION SYSTEMS FOR BIOPHARMACEUTICALS | 122 |
| 3.1. Using Microbes for Biopharming | 122 |

| | |
|--|------------|
| 3.2. Using Mammalian Cell Lines for Biopharming | 122 |
| 3.3. Using GM Animals for Biopharming | 123 |
| 3.4. Using GM Crops for Biopharming | 123 |
| 4. TYPES OF PLANT-BASED BIOPHARMACEUTICAL PRODUCTS | 124 |
| 4.1. Antibodies | 124 |
| 4.2. Vaccines | 125 |
| 4.3. Other Therapeutic Agents | 125 |
| 5. TRANSGENIC PLANTS IN THE BIOPHARMACEUTICAL MARKET | 126 |
| 6. METHODOLOGICAL ASPECTS OF PLANT-BASED BIOPHARMACEUTICALS | 127 |
| 6.1. Upstream Processing | 128 |
| 6.1.1. <i>Plant Transformation</i> | 128 |
| 6.1.2. <i>Media Hydration</i> | 131 |
| 6.1.3. <i>Cell Culture (Bioreactor)</i> | 131 |
| 6.2. Harvesting | 132 |
| 6.2.1. <i>Harvesting from Plant Material (Centrifugation or Filtration)</i> | 132 |
| 6.3. Downstream Processing of the Proteins of Pharmaceutical Value | 133 |
| 6.3.1. <i>Protein Extraction</i> | 134 |
| 6.3.2. <i>Clarification</i> | 134 |
| 6.3.3. <i>Flocculation</i> | 135 |
| 6.3.4. <i>Protein Purification</i> | 135 |
| 7. RECENT ADVANCES IN BIOPHARMACEUTICAL PRODUCTION | 138 |
| 7.1. Cell and Tissue Culture | 138 |
| 7.2. Virus-infected Plants – A Valuable Therapeutic Protein Production Source | 141 |
| 7.3. Expression of Therapeutic Proteins in Plants Through Agro-infection | 142 |
| 8. QUALITY ASSURANCE IN BIOPHARMACEUTICAL PRODUCTION | 144 |
| 8.1. Biopharmaceutical Production Validation | 145 |
| 9. APPLICATIONS OF BIOPHARMACEUTICAL FOR VETERINARY AND HUMANS | 147 |
| 10. PROSPECTS | 149 |
| CONSENT FOR PUBLICATION | 150 |
| CONFLICTS OF INTEREST | 150 |
| ACKNOWLEDGMENTS | 150 |
| REFERENCES | 150 |
| CHAPTER 7 GREEN FACTORIES: PLANTS AS A PLATFORM FOR COST-EFFECTIVE PRODUCTION OF HIGH-VALUE TARGETS | 162 |
| <i>Muhammad Omar Khan, Ayesha Siddiqui and Niaz Ahmad</i> | |
| 1. WHY PLANT-BASED EXPRESSION SYSTEMS? | 162 |
| 2. DEVELOPMENT OF TRANSGENIC PLANTS | 167 |
| 3. SUMMARY AND OUTLOOK | 180 |
| CONSENT FOR PUBLICATION | 182 |
| CONFLICT OF INTEREST | 182 |
| ACKNOWLEDGMENTS | 182 |
| REFERENCES | 182 |
| CHAPTER 8 ANALYSIS OF CROSS-REACTIVITY, SPECIFICITY AND THE USE OF OPTIMISED ELISA FOR RAPID DETECTION OF <i>FUSARIUM</i> SPP. | 195 |
| <i>Phetole Mangena and Phumzile Mkhize</i> | |
| 1. INTRODUCTION | 196 |
| 2. FUNGAL DISEASES AND HOST RANGE OF <i>FUSARIUM</i> SPP. INFECTING PLANTS AND ANIMALS | 199 |
| 3. DETECTION SYSTEMS FOR <i>FUSARIUM</i> PATHOGENS | 202 |
| 3.1. Traditional and Current Methods of Fusarium Detection | 203 |

| | |
|---|-----|
| 3.2. Limitations in the Traditional and Current <i>Fusarium</i> Detection Systems | 204 |
| 4. ANTIBODY REACTIVITY AND SPECIFICITY INVOLVING <i>FUSARIUM</i> SPP. | 205 |
| 5. NATURE OF ANTIGEN VARIATION AND DISTRIBUTION | 207 |
| 6. ANTIBODY RECOGNITION | 208 |
| 6.1. Epitope Structure and Functionality | 210 |
| 6.2. Paratope Binding | 211 |
| 6.3. Maturation of Antibody Specificity | 211 |
| 6.4. Contrast Binding Affinity and Specificity | 212 |
| 7. DIVERSITY OF <i>FUSARIUM</i> ANTIBODIES AND THEIR SPECIFICITY | 212 |
| 8. CROSS-REACTIVITY IN MONOCLONAL AND POLYCLONAL ANTIBODIES AGAINST <i>FUSARIUM</i> ANTIGENS | 213 |
| 9. DEVELOPMENT OF OPTIMISED ELISA FOR RAPID DETECTION OF <i>FUSARIUM</i> SPECIES | 215 |
| FINAL CONSIDERATIONS OR CONCLUSIONS | 216 |
| ABBREVIATIONS | 217 |
| CONSENT FOR PUBLICATION | 217 |
| CONFLICT OF INTEREST | 217 |
| ACKNOWLEDGEMENTS | 217 |
| REFERENCES | 218 |
| CHAPTER 9 PLANT MOLECULAR PHARMING FOR HUMAN DISEASES | 226 |
| <i>Kiran Saba, Muhammad Suleman Malik, Sara Latif, Fatima Ijaz, Muhammad Sameeullah and Mohammad Tahir Waheed</i> | |
| 1. INTRODUCTION | 226 |
| 2. MILLENNIUM DEVELOPMENT GOALS (MDGS) | 229 |
| 3. SUSTAINABLE DEVELOPMENT GOALS (SDGS) | 231 |
| 3.1. Role of Plant Molecular Pharming in Achieving Sustainable Development Goals | 233 |
| 4. CURRENT STATUS OF MOLECULAR PHARMING IN THE LAST DECADE FOR EMERGING INFECTIOUS DISEASES | 234 |
| 4.1. Chikungunya | 244 |
| 4.2. Crimean-Congo Hemorrhagic Fever | 244 |
| 4.3. Ebola Virus Disease | 245 |
| 4.5. Human Respiratory Syncytial Virus | 245 |
| 4.6. Influenza | 246 |
| 4.7. Marburg Virus Disease | 247 |
| 4.8. Rift Valley Fever | 247 |
| 4.9. Severe Acute Respiratory Syndrome | 248 |
| 4.10. Nipah Virus Disease | 248 |
| 4.11. Zika Virus Disease | 249 |
| CONCLUDING REMARKS | 249 |
| CONSENT FOR PUBLICATION | 249 |
| CONFLICT OF INTEREST | 249 |
| ACKNOWLEDGEMENTS | 249 |
| REFERENCES | 250 |
| CHAPTER 10 PLANT MOLECULAR FARMING FOR HUMAN THERAPEUTICS: RECENT ADVANCES AND FUTURE PROSPECTS | 267 |
| <i>Amna Ramzan, Zainab Y. Sandhu, Saba Altaf, Aisha Tarar, Iqra Arshad, Sumera Rashid, Huma Shakoore, Rabia Abbas and Bushra Rashid</i> | |
| 1. INTRODUCTION | 268 |
| 2. SIGNIFICANCE OF PLANT MOLECULAR FARMING (PMF) APPLICATIONS | 269 |
| 2.1. Recombinant Antibodies | 270 |

| | |
|--|------------|
| 2.2. Edible Vaccines | 272 |
| 2.3. Biocatalysts | 273 |
| 2.4. Biopolymers | 274 |
| 2.5. Feed Additives | 274 |
| 2.6. Biofuel | 275 |
| 3. SUITABLE PLANT MOLECULAR FARMING PRODUCTION SYSTEM | 276 |
| 3.1. Food/Feed Crops | 276 |
| 3.2. Non-Food/Feed Crops | 277 |
| 4. LIMITATIONS AND OPTIMIZATIONS OF PMF PLATFORMS | 278 |
| 4.1. Optimizing Transcript Expression | 278 |
| 4.2. Optimizing Protein Stability | 278 |
| 5. BIOSAFETY AND REGULATORY ISSUES | 280 |
| 6. POTENTIAL SOLUTIONS FOR BIOSAFETY CONCERNS | 281 |
| 6.1. Use of Non-Food Crops and Non-Crop Plants | 282 |
| 6.2. Use of Cell Cultures of Transgenic Plants | 283 |
| 6.3. Use of Physical and Spatial Containments | 283 |
| 7. PLANT TRANSFORMATION TECHNIQUES | 284 |
| 8. PURIFICATION OF RECOMBINANT PROTEIN PRODUCTS | 286 |
| 9. FUTURE PROSPECTIVE | 287 |
| CONCLUSION | 288 |
| CONSENT FOR PUBLICATION | 288 |
| CONFLICT OF INTEREST | 288 |
| ACKNOWLEDGEMENTS | 288 |
| REFERENCES | 288 |

CHAPTER 11 PROTEINS AND PEPTIDES AS BIOMARKERS FOR DIAGNOSIS OF CARDIOVASCULAR DISEASES 298

Sehar Aslam, Samman Munir, Muhammad Shareef Masoud, Usman Ali Ashfaq, Nazia Nahid, Mohsin Khurshid and Muhammad Qasim

| | |
|--|------------|
| 1. INTRODUCTION | 298 |
| 2. BIOMARKERS FOR CVD | 299 |
| 2.1. Myocardial Stress | 301 |
| 2.1.1. Atrial Natriuretic Peptides | 301 |
| 2.1.2. B-type Natriuretic Peptides | 301 |
| 2.1.3. Copeptin | 302 |
| 2.2. Myocardial Injury | 303 |
| 2.2.1. Cardiac Troponin | 303 |
| 2.2.2. Cardiac Myosin-binding Protein C | 304 |
| 2.3. Inflammation | 304 |
| 2.3.1. Interleukin-6 | 304 |
| 2.3.2. C-reactive Protein | 305 |
| 2.3.3. Galectin-3 | 305 |
| 2.3.4. Growth Differentiation Factor 15 (GDF-15) | 306 |
| 2.3.5. Suppressor of Tumorigenicity 2 (ST2) | 306 |
| 2.4. Plaque Instability | 306 |
| 2.4.1. Matrix Metalloproteinase-9 (MMP-9) | 307 |
| 2.4.2. Lipoprotein-associated Phospholipase A2 (Lp-PLA2) | 307 |
| 2.5. Calcium Homeostasis | 307 |
| 2.5.1. Secretoneurin | 307 |
| 2.6. Platelet Activation | 308 |
| 2.6.1. P-selectin | 308 |

| | |
|--|------------|
| 2.6.2. CD40 Ligand | 308 |
| 2.7. Systemic Stress | 309 |
| 2.7.1. Granin Proteins | 309 |
| 2.7.2. Catecholamines | 309 |
| 3. EXPERIMENTAL TECHNIQUES DESIGN FOR SELECTION OF PROTEIN BIOMARKERS OF CARDIOVASCULAR DISEASE | 310 |
| 4. FROM DISCOVERY TO CLINICAL VALUE: STATUS AND PERSPECTIVE | 310 |
| 5. MULTI-MARKER APPROACHES | 311 |
| 6. LIMITATIONS OF PROTEINS/PEPTIDES AS BIOMARKERS FOR CV DISEASES ... | 312 |
| CONCLUSION | 313 |
| CONSENT FOR PUBLICATION | 313 |
| CONFLICTS OF INTEREST | 314 |
| ACKNOWLEDGEMENTS | 314 |
| REFERENCES | 314 |
| SECTION III: MOLECULAR PHARMING FOR ANIMALS | |
| CHAPTER 12 VETERINARY NUTRACEUTICS, PHARMACEUTICS AND VACCINE | 323 |
| <i>Amjad Islam Aqib1, Muhammad Shoaib, Muhammad Aamir Naseer, Saad Ahmad, Mubashrah Mahmood, Faisal Siddique, Tean Zaheer, Aisha Mahmood and Iqra Muzammil</i> | |
| 1. INTRODUCTION | 324 |
| 2. VETERINARY ORIGIN NUTRACEUTICS | 325 |
| 3. VETERINARY PHARMACEUTICS | 327 |
| 3.1. Role of Transgenic Animals in Pharmaceutical Industry | 327 |
| 3.2. Hormones and Enzymes of Animal Origin Use in Pharmaceutical Industry | 329 |
| 3.3. Milk Proteins of Pharmaceutical Importance | 332 |
| 3.3.1. Bovine Milk Proteins | 332 |
| 3.3.2. Camel Milk Proteins | 333 |
| 3.3.3. Sheep / Goat Milk Proteins | 334 |
| 4. VETERINARY PEPTIDE AND PROTEIN BASED VETERINARY VACCINES | 334 |
| 4.1. Role of Animals in Passive Immunization | 336 |
| 4.2. Animal Derived Antibodies | 337 |
| 4.3. Animal Derived Nanobodies | 338 |
| 4.3.1. Role of Nanobodies in Drug Delivery and Biomarker Detection | 339 |
| 4.3.2. Nanobody as an Indicator in Diagnostics and Molecular Imaging | 340 |
| 4.3.3. The Role of Nanobodies in the Treatment of Diseases | 340 |
| CONCLUSION | 341 |
| CONSENT FOR PUBLICATION | 341 |
| CONFLICT OF INTEREST | 341 |
| ACKNOWLEDGEMENTS | 341 |
| REFERENCES | 341 |
| CHAPTER 13 PLANT MOLECULAR PHARMING FOR LIVESTOCK AND POULTRY | 349 |
| <i>Rimsha Riaz, Saher Qadeer, Faiz Ahmad Joyia, Ghulam Mustafal and Muhammad Sarwar Khan</i> | |
| 1. INTRODUCTION | 349 |
| 2. GLOBAL IMPORTANCE OF LIVESTOCK AND POULTRY SECTORS | 351 |
| 3. ANIMALS TO HUMAN SPREAD OF DISEASES | 352 |
| 4. EMERGENCE AND RE-EMERGENCE OF NEW DISEASES | 352 |
| 5. LIMITATIONS OF CURRENTLY USED VACCINES FOR LIVESTOCK AND POULTRY | 353 |

| | |
|--|----------|
| 6. TYPES OF VACCINES FOR ANIMALS AND POULTRY | 354 |
| 6.1. Conventional Live and Inactivated Vaccines: | 355 |
| 6.2. Subunit Vaccines | 356 |
| 6.3. Genetically Modified Organisms | 356 |
| 6.4. DNA-Based Vaccines | 357 |
| 7. PLANT-BASED EXPRESSION PLATFORM FOR VACCINE PRODUCTION | 358 |
| 8. IMPORTANT LIVESTOCK AND POULTRY DISEASES AND THEIR PLANT-BASED VACCINES | 364 |
| 8.1. Infectious Bursal Disease (IBD) | 364 |
| 8.2. Newcastle Disease (ND) | 367 |
| 8.3. Foot-and-Mouth Disease (FMD) | 368 |
| 9. A CURRENT MARKET SCENARIO OF PLANT-BASED THERAPEUTICS FOR LIVESTOCK AND POULTRY DISEASES | 372 |
| CONSENT FOR PUBLICATION | 373 |
| CONFLICT OF INTEREST | 373 |
| ACKNOWLEDGEMENTS | 373 |
| REFERENCES | 373 |
| SUBJECT INDEX | 5: 6 |

PREFACE

Manufacturing pharmaceuticals cost-effectively is one of the items on the wish list of biochemists and biotechnologists as drug regulatory authority in the USA has approved large-scale production and clinical trials of drugs developed through diverse production routes, including viruses, animals, and plants. Several factors are taken into account while selecting a production system of recombinant proteins since different expression systems have their own merits and demerits. The cost of expressed recombinant proteins includes production, processing, and purification costs. Normally, the production of expressed proteins costs around 70%, whereas purification costs around 30% of the total cost. Molecular pharming refers to the production of recombinant pharmaceutical proteins using plant biotechnology. This volume covers an array of topics relevant to structure, function, regulation, and mechanisms of action, biochemical significance, and usage of proteins and peptides as biomarkers, therapeutics, and vaccines for animals and human beings. Further, this book highlights the current progress from three directions, including system biology – *in silico* characterization of proteins and peptides, molecular pharming for animals, and molecular pharming for humans.

The book, *Frontiers in Molecular Pharming*, consists of 13 chapters subdivided into three sections. The chapters in the book are strategically organized to allow easy reading. Section I (System Biology – *in silico* Characterization of Proteins and Peptides) begins with Chapter 1 in which Dr. Rahman and his colleagues very comprehensively highlight various bioinformatics tools for predicting epitopic regions and a variety of immunological techniques to monitor the immune response generated against selected epitopic regions for the development of vaccines and diagnostics. Dr. Tahir ul Qamar and his colleagues in Chapter 2 have discussed the recent progress in the emerging field of immunoinformatics and its role in vaccine development. Dr. Ali explains the computational toolbox and its use in determining protein stability and analysis to improve thermostability in Chapter 3. In Chapter 4, Dr. Chen and her colleagues suggest how an evolving approach to Pan-proteomics is complementing our understanding of the functional complexity of emerging and highly virulent pathogens and their resistance development against drugs. Further, in Chapter 5, Drs. Haider and Niazi briefly overview the computational methods to predict the biological roles of peptides and proteins for medical or industrial applications.

Section II (Molecular Pharming for Human Beings) consists of six chapters, *i.e.*, Chapters 6 through 11. In Chapter 6, Dr. Khan and his team members explain comprehensively how diverse expression systems could be used to costeffectively develop recombinant pharmaceuticals and their application to control diseases in animals and human beings. Dr. Ahmad and his team provide a snapshot of different expression systems and argue that the plant-based expression system is highly commercially feasible not only for the production of high-value targets but also to address global challenges like COVID-19 in Chapter 7. In Chapter 8, Drs. Mangena and Mkhize explain the role of antibody cross-reactivity and specificity concerning basic principles, challenges, and detection for rapid and reliable assessment in *Fusarium* pathogens. Dr. Waheed and his team in Chapter 9 and Dr. Rashid and her team in Chapter 10 have discussed how the requisition of plant-based medicine is increasing day-by-day with its perspective to human diseases, and several advantages owing to United Nations' sustainable development goals (SDGs). Dr. Qasim and his colleagues in Chapter 11 explain the importance of proteins and peptides as biomarkers for the diagnosis of cardiovascular diseases to improve the risk prediction at the population level. Further, the authors explore how new technologies and innovations can be applied to advance the science of vaccine-associated biomarkers.

Section III (Molecular Pharming for Animals) consists of two chapters. In Chapter 12, Dr. Aqib and his colleagues highlight the history and recent trends in veterinary pharmaceuticals and vaccines. They further discuss the nutraceutical potential of animal products as one of the fascinating areas of research with considerable anti-microbial, anti-cancer, anti-inflammatory, anti-diabetic, and neuroprotective functions. Dr. Khan and his team in Chapter 13 highlight the importance of plant-based gene expression systems that have been exploited as bioreactors for the cost-effective production of pharmaceuticals, predominantly for the expression and accumulation of antigenic proteins, to be used as vaccines for livestock and poultry. Further, they have discussed various types of vaccines keeping in view diseases like Infectious Bursal Disease (IBD), New Castle Disease (ND), and Foot and Mouth Disease (FMD).

Molecular farming is progressively reaching the stage of being considered as an economical alternative to established systems for the production of pharmaceuticals. Thus, this volume serves as a treasured resource for students and professionals of molecular biology, biotechnology, medicinal chemistry, and organic chemistry.

Muhammad Sarwar Khan
Centre of Agricultural Biochemistry and
Biotechnology (CABB)
University of Agriculture
Faisalabad
Pakistan

List of Contributors

- Aamir Shehzad** Drug Discovery and Structural Biology Group, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan
Pakistan Institute of Engineering and Applied Sciences (PIEAS), National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan
- Adnan K. Niazi** Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture Faisalabad, Faisalabad, 38040, Pakistan
- Aisha Mahmood** Department of Physiology, Faculty Of Veterinary And Animal Sciences, The Islamia University of Bahawalpur, Bahawalpur, Pakistan
- Aisha Tarar** Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
- Amjad Ali** Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan
- Amjad Islam Aqib** Department of Medicine, Faculty of Veterinary Science, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, 63100, Pakistan
- Amna Bari** Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, P. R. China
- Amna Ramzan** Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
- Anam Naz** Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan
- Ayesha Siddiqui** Agricultural Biotechnology Division, National Institute for Biotechnology & Genetic Engineering (NIBGE), Jhang Road, Faisalabad, 38000, Pakistan
Department of Biotechnology, Pakistan Institute of Engineering and Applied Sciences(PIEAS) , Nilore, Islamabad, Pakistan
- Barira Zahid** Key Laboratory of Horticultural Plant Biology (Ministry of Education), College of Horticulture and Forestry, Huazhong Agricultural University, Wuhan, P. R. China
- Bushra Rashid** Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
- Faisal Siddique** Department of Microbiology, Faculty of Veterinary Science, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, 63100, Pakistan
- Faiz Ahmad Joyia** Centre of Agricultural Biochemistry & Biotechnology (CABB), University of Agriculture, Faisalabad, Pakistan
- Farah Shahid** Department of Bioinformatics and Biotechnology, Government College University Faisalabad, Faisalabad, Pakistan
- Fatima Ijaz** Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan

- Fatima Khalid** Key Laboratory of Horticultural Plant Biology (Ministry of Education), College of Horticulture and Forestry, Huazhong Agricultural University, Wuhan, P. R. China
- Feng Xing** College of Life Science, Xinyang Normal University, Xinyang 464000, P. R. China
- Ghulam Mustafa** Centre of Agricultural Biochemistry & Biotechnology (CABB), University of Agriculture, Faisalabad, Pakistan
- Huma Shakoor** Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
- Iqra Arshad** Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
- Iqra Mehmood** Department of Bioinformatics and Biotechnology, Government College University Faisalabad, Faisalabad, Pakistan
- Iqra Muzammil** Department of Veterinary Medicine, Faculty of Veterinary Science, University of Veterinary and Animal Sciences, Lahore, 54000, Pakistan
- Jia-Ming Song** State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, College of Life Science and Technology, Guangxi University, Nanning, P. R. China
Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, P. R. China
- Kiran Saba** Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
- Kishver Tusleem** Sir Ganga Ram Hospital, Fatima Jinnah Medical University, Lahore, Pakistan
- Ling-Ling Chen** State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, College of Life Science and Technology, Guangxi University, Nanning, P. R. China
Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, P. R. China
- Majid Ali Shah** Drug Discovery and Structural Biology Group, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan
Pakistan Institute of Engineering and Applied Sciences (PIEAS), National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan
- Maryam Zafar** Drug Discovery and Structural Biology Group, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan
Pakistan Institute of Engineering and Applied Sciences (PIEAS), National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan

| | |
|--------------------------------|--|
| Mazhar Iqbal | Drug Discovery and Structural Biology Group, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan Pakistan Institute of Engineering and Applied Sciences (PIEAS), National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan |
| Moazur Rahman | Drug Discovery and Structural Biology Group, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan School of Biological Sciences, University of the Punjab, Lahore, Pakistan |
| Mohammad Tahir Waheed | Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan |
| Mohsin Khurshid | Department of Microbiology, Government College University, Faisalabad, Pakistan |
| Mubashrah Mahmood | Department of Theriogenology, Faculty of Veterinary Science, University of Agriculture, Faisalabad, 38000, Pakistan |
| Muhammad Aamir Naseer | Department of Clinical Medicine and Surgery, Faculty of Veterinary Science, University of Agriculture, Faisalabad, 38000, Pakistan |
| Muhammad Omar Khan | Agricultural Biotechnology Division, National Institute for Biotechnology & Genetic Engineering (NIBGE), Jhang Road, Faisalabad, 38000, Pakistan Department of Biotechnology, Pakistan Institute of Engineering and Applied Sciences(PIEAS) , Nilore, Islamabad, Pakistan |
| Muhammad Sameeullah | Innovative Food Technologies Development Application and Research Center, Faculty of Engineering, Bolu Abant Izzet Baysal University, 14030, Bolu, Turkey |
| Muhammad Sarwar Khan | Center of Agricultural Biochemistry and Biotechnology, University of Agriculture, Faisalabad, Pakistan |
| Muhammad Shareef Masoud | Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan |
| Muhammad Shoaib | Institute of Microbiology, Faculty of Veterinary Science, University of Agriculture, Faisalabad, 38000, Pakistan |
| Muhammad Qasim | Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan |
| Muhammad Suleman Malik | Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan |
| Muhammad Tahir ul Qamar | College of Life Science and Technology, Guangxi University, Nanning, P. R. China |
| Nazia Nahid | Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan |
| Niaz Ahmad | Agricultural Biotechnology Division, National Institute for Biotechnology & Genetic Engineering (NIBGE), Jhang Road, Faisalabad, 38000, Pakistan Department of Biotechnology, Pakistan Institute of Engineering and Applied Sciences(PIEAS) , Nilore, Islamabad, Pakistan |

| | |
|-------------------------|--|
| Phetole Mangena | Department of Biodiversity, School of Molecular and Life Sciences, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, Republic of South Africa |
| Phumzile Mkhize | Department of Microbiology, Biochemistry and Biotechnology, School of Molecular and Life Sciences, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, Republic of South Africa |
| Rabia Abbas | Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan |
| Rimsha Riaz | Center of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture, Faisalabad – 38040, Pakistan |
| Saad Ahmad | Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Lanzhou, China |
| Saba Altaf | Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan |
| Saher Qadeer | Center of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture, Faisalabad – 38040, Pakistan |
| Sajjad Ahmad | Department of Health and Biological Sciences, Abasyn University, Peshawar, Pakistan |
| Samman Munir | Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan |
| Sara Latif | Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan |
| Soban Tufail | Drug Discovery and Structural Biology Group, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan Pakistan Institute of Engineering and Applied Sciences (PIEAS), National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan |
| Sumera Rashid | Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan |
| Syed Farhat Ali | School of Life Sciences, Forman Christian College (A Chartered University), Lahore, Pakistan |
| Tean Zaheer | Department of Parasitology, Faculty of Veterinary Science, University of Agriculture, Faisalabad, 38000, Pakistan |
| Usman Ali Ashfaq | Department of Bioinformatics and Biotechnology, Government College University Faisalabad, Faisalabad, Pakistan |
| Xitong Zhu | Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, P. R. China |
| Zainab Y. Sandhu | Montclair State University, New Jersey NJ 07043, USA |
| Zeshan Haider | Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture Faisalabad, Faisalabad, 38040, Pakistan State Key Laboratory of Grassland Agro-Ecosystems, College of Pastoral Agriculture Science and Technology, Lanzhou University, Lanzhou, China |

**SECTION I: System Biology – *In silico*
Characterization of Proteins and Peptides**

CHAPTER 1

Tools for Prediction and Validation of Epitopic Regions on Protein Targets for Vaccine Development and Diagnostics

Soban Tufail^{1,2}, Majid Ali Shah^{1,2}, Maryam Zafar^{1,2}, Mazhar Iqbal^{1,2}, Amjad Ali³, Aamir Shehzad^{1,2,*} and Moazur Rahman^{1,4,*}

¹ Drug Discovery and Structural Biology Group, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan

² Pakistan Institute of Engineering and Applied Sciences (PIEAS), P.O. Nilore, Islamabad, Pakistan

³ Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan

⁴ School of Biological Sciences, University of the Punjab, Lahore, Pakistan

Abstract: Epitopes are parts of an antigen that are recognized by the immune system. Identification of epitopic regions on an immunogenic protein is important for several clinical and biotechnological applications. Various bioinformatics tools are currently available which can be used for the prediction of epitopic regions, and the immune response generated against selected epitopic regions can be monitored through a variety of immunological techniques. In this chapter, we provide an overview of widely used *in silico* tools for the prediction of epitopic regions, followed by biophysical methods used for their characterization. Furthermore, a brief description of important immunological approaches for measuring immune responses elicited by epitopes is also given. It is anticipated that the information provided in this chapter will help researchers in selecting appropriate tools for the prediction and validation of epitopes on a protein target for vaccine development and diagnostics.

Keywords: Diagnostics, Epitope prediction, Protein targets, Vaccine.

* Corresponding authors Moazur Rahman & Aamir Shehzad: School of Biological Sciences, University of the Punjab, Lahore, Pakistan; Tel: +92 42 99230960; Fax: +92 42 99230980; E-mails: moaz.sbs@pu.edu.pk, moazur.rahman@fulbrightmail.org, & Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan; Tel: +92 41 9201316-9; Ext 242; Fax: +92 41 9201322; E-mail: aamiruopbbt@yahoo.com

1. IMMUNE SYSTEM-AN OVERVIEW

A properly functioning immune system plays a key role in neutralizing ‘biological threats’ posed by infectious diseases and cancer. Understanding the immune system is important for devising therapeutic interventions to cure various diseases. The immune system is categorized into innate and adaptive subsystems. The innate immune system, which is non-specific, is the first line of defense against infections. On the other hand, the adaptive immune system, which is highly specific, is only found in vertebrates. Adaptive immune responses are orchestrated by lymphocytes, namely B- and T-cells, which induce humoral and cell-mediated immunity.

Importantly, specific receptors present on the surface of B- and T-cells recognize molecular components, commonly known as antigens, of pathogens. B-cell receptors, which consist of membrane-bound immunoglobulins, usually recognize parts of antigens that are solvent-exposed. Activated B-cells produce soluble immunoglobulins, also known as antibodies, which are involved in humoral adaptive immunity. The humoral immune system not only enables the recognition of antigenic determinants in pathogenic proteins but also induces the formation of memory B-cells which generate a strong antibody-mediated immune response upon re-infection. On the other hand, T-cell receptors recognize antigens by binding to antigenic peptides attached to the groove of major histocompatibility complex (MHC) molecules, also known as human leukocyte antigen (HLA) in humans, on the surface of antigen-presenting cells (APCs). In humans, the HLA system is polygenic (encoded by 21 genes on chromosome 6) and highly polymorphic. There are two distinct subtypes of T-cells, phenotypically classified as CD8⁺ and CD4⁺ T-cells, which recognize linear antigenic peptides presented by MHC molecules. Activated CD8⁺ T-cells, also known as cytotoxic T lymphocytes (CTLs), recognize peptides presented by MHC class I molecules (Fig. 1). These peptides, which are typically 9 amino acids long, presented by MHC class I molecules originate from intracellular antigens degraded in the cytosol. Activated CD4⁺ T-cells, also known as T helper (Th) cells, recognize antigenic peptides presented by MHC class II molecules and are specific to extracellular antigens which have been endocytosed, degraded, and complexed to MHC class II molecules in endosomal compartments [1]. Typically, peptides attached to MHC class II molecules are 15 amino acids in length and protrude out of the peptide-binding groove of MHC class II molecules [2].

Portions of antigens that are recognized by B- and T-cells are known as epitopes. Discrete regions of antigens that are recognized by B-cell receptors or secreted antibodies and can evoke the humoral immune response are known as B-cell epitopes [3]. It has been found that B-cell epitopes predominantly consist of

solvent-exposed (hydrophilic) regions which are located on the surface of antigens [4, 5]. B-cell epitopes can be linear (continuous) or conformational (discontinuous). Linear epitopes are comprised of a contiguous stretch of amino acids of an antigen [6, 7]. Conformational epitopes consist of amino acids that are not contiguous, and residues critical for recognition by antibodies are located nearby due to the folded three-dimensional structure of a given antigen. It has been observed that the majority of conformational epitopes (more than 70%) contain 1-5 short linear segments of amino acids [5]. Moreover, most B-cell epitopes (~90%) are conformational epitopes [8, 9]. T-cell epitopes are MHC binding peptides (ligands) that elicit a T-cell immune response. Upon recognition of a T-cell epitope, T-cells produce a long-lived memory population that confers on the host the ability to respond swiftly when the same epitope is encountered again [10, 11].




Fig. (1). Graphical illustrations of genes encoding MHC molecules and recognition of MHC-bound peptides by T cells. **(A)** The location of genes encoding MHC class I and MHC class II molecules on chromosome 6 in humans. **(B)** Recognition of peptides bound to MHC class I molecules on antigen-presenting cells by cytotoxic T cells. **(C)** The interaction of a foreign antigen with a B-cell receptor leads to the presentation of the foreign peptide to T helper cells through MHC class II molecules on the surface of B-cells. Activated B-cells proliferate and differentiate into memory B-cells and antibody-producing plasma cells.

Immunoinformatics and its Role in Vaccine Development

Iqra Mehmood¹, Amna Bari², Sajjad Ahmad³, Anam Naz⁴, Farah Shahid¹, Usman Ali Ashfaq¹, Kishver Tusleem⁵ and Muhammad Tahir ul Qamar^{6,*}

¹ Department of Bioinformatics and Biotechnology, Government College University Faisalabad, Faisalabad, Pakistan

² Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, P. R. China

³ Department of Health and Biological Sciences, Abasyn University, Peshawar, Pakistan

⁴ Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan

⁵ Sir Ganga Ram Hospital, Fatima Jinnah Medical University, Lahore, Pakistan

⁶ College of Life Science and Technology, Guangxi University, Nanning, P. R. China

Abstract: Immunoinformatics is currently an emerging field that has accelerated immunological research to a great extent. It is playing a significant role in antigen identification, immunodiagnostic development, and vaccine design. The arrival of genome sequencing with recent advancements in immunoinformatics has provided a lot of data that can be annotated using databases and tools to reduce the cost required for antibody and vaccine development, ultimately saving time, cost, and resources. The selection and identification of immunogenic regions from the pathogen genomes by computational methods play an important role in devising new hypotheses by a comprehensive examination of immunologic data composite, which is otherwise impossible to achieve by using traditional methods alone. Presently, many epitope-based vaccines, especially multi-epitope vaccines designed employing immunoinformatics approaches, are successfully trailed and being developed against pathogens. In this chapter, we provide an outline of the recent progress in the field of vaccinology and immunoinformatics, enlisted recent tools and databases available for epitopes prediction, validation, and vaccine design, and give a brief description of the role of immunoinformatics in vaccine design against recent COVID-19.

Keywords: Computationally designed vaccines, Immunoinformatics, Reverse vaccinology, Subtractive genomics.

* Corresponding author Muhammad Tahir ul Qamar: College of Life Science and Technology, Guangxi University, Nanning, P. R. China; Tel: +8615271915965; ORCID: 0000-0003-4832-4250; E-mail: m.tahirulqamar@hotmail.com

Muhammad Sarwar Khan (Ed)
All rights reserved-© 2021 Bentham Science Publishers

1. INTRODUCTION

Vaccination is an important approach that involves the designation of vaccines and its administration in the host to protect them from various diseases [1]. The immunization journey started with the discovery of a vaccine against smallpox by Edward Jenner in 1798 [2]. Later on, many vaccines have been developed, and some are still in the process against emerging diseases. Various conventional methods being used for vaccine development generally involved inactivated or live attenuated vaccines [3], nucleic acid vaccines [4], subunit vaccines [5], and virus-like particles [6], which are discussed separately in a later section of this chapter. All these methods are generally *in vitro* and have many complications and limitations associated with them. For example, inactivated vaccines, if not properly designed, can reactivate in the host and cause diseases. Additionally, some vaccines require boosters for working effectively at later stages because they are unable to generate a robust immune response in the first attempt [2, 7, 8].

In the recent decade, whole-genome sequencing of humans and other organism resulted in a huge amount of functional, epidemiological, and clinical data [9, 10]. This assembled information available in specialist repositories and databases enables the researchers to get deep insights into the mechanisms of human diseases and to understand host immune responses. Computational immunology or immunoinformatics deals with such rapidly growing immunological data [11 - 13]. Immunoinformatics is now a crucial constituent of modern immunology research and correlates with experimental immunology and computer science. It utilizes computational resources and methods to understand, generate, process, and propagate immunological information. Immunoinformatics came into being 90 years ago with the hypothetical demonstration of malarial epidemiology [11, 12]. This emerging field includes various databases and tools that manage the observation of immunologic records produced by tentative researchers and assist in introducing and representing new therapeutic targets [14, 15]. It seems to provide the platform to develop and progress immunological research in less time. Vaccine informatics successfully utilized various bioinformatics methods and applications to accommodate different locations of the preclinical, clinical, and licensed vaccine activities. Also, the advancement in immunology and molecular biology facilitates the improvement of epitope-based vaccines, which has become a way for further research of molecular vaccines [15 - 18]. Furthermore, reverse vaccinology can expand vaccine protocols, design, and production by predicting various protein-vaccine candidates within genomes using computational approaches [19]. Immunoinformatics allow the potential B and T cell epitope prediction within selected candidate proteins, which can elicit a proper immune response against the pathogen. It has provided ease in the analysis, vaccine

design, immunization modeling, and evaluation of vaccine efficacy and safety [18, 20, 21].

In silico vaccine design, immunoproteomics, immunogenomics, and epitope prediction are some areas of Immunoinformatics. Recently, system biology methodologies have also been used to understand the various aspects and variable behavior of the complex immune system [22]. It constitutes the utilization of computational resources and methods to understand immunological evidence. It is a recent advancement in bioinformatics that uses numerous computational approaches to identify, understand, and predict a wide range of interactions among antigens and host immune system's receptors, including major histocompatibility complex (MHC) receptors also B and T cell receptors [23]. Immunoinformatics not merely aids in handling enormous data but also plays a crucial role in explaining new hypotheses associated with immune responses [24]. It is a potential and advantageous approach since conventional methods for vaccine development needs viruses to cultivate for understanding their binding patterns and to extract their antigenic proteins [25]. The term “Immunome” is used for all the data of proteins and genes in the immune system, excluding proteins and genes present in other cells except immune cells [26]. Immunoreactions that result from reactions between host cell proteins and antigens are referred to as immunome reactions, and the study of these reactions is called Immunomics [27]. Immunomics is a branch of knowledge that deals with the use of high throughput methods and techniques to determine and understand mechanisms involved in the immune system [28, 29]. In this chapter, we will briefly discuss the transformation of traditional vaccinology into modern vaccinology, recent advancements in immunoinformatics, important tools, and databases for prediction and validation of epitopes for vaccine design, and the role of immunoinformatics in COVID-19 vaccine development. It is anticipated that the information provided in this chapter will help researchers in choosing the most suitable tools and approaches for vaccine designs and immunological diagnostics development.

2. TRANSFORMATION OF VACCINOLOGY FROM CONVENTIONAL TO MODERN ERA

Previously, in the absence of effective therapies and preventive methods; infectious diseases such as measles, smallpox, diphtheria, rubella, chickenpox, and influenza were top listed child killers. Fortunately, these devastating diseases have diminished in various developed countries due to the widespread distribution and evolution of effective, safe, and affordable vaccines [30]. Vaccines can stop pathogens before they cause life-threatening damage, and millions of lives have

Computational Toolbox for Analysis of Protein Thermostability

Syed Farhat Ali^{1,*}

¹ School of Life Sciences, Forman Christian College (A Chartered University), Lahore, Pakistan

Abstract: Thermostable proteins have many applications. They have utility in food and beverages, paper and pulp industries, animal feed production, laundry and detergent, and molecular biology and diagnostics. Many factors contribute to protein thermostability. These include covalent and non-covalent interactions, protein folding and conformation, and other thermodynamic factors. Although the available protein structures have been increasing over time, the increase in available protein sequences is overwhelmingly enormous. Also, structure determination can be a challenging job and many proteins are difficult to crystallize. This has resulted in a sequence-structure gap. The use of computer-assisted structure prediction has helped in filling this gap. There are many *in silico* strategies and methods available to predict and analyze protein structure and properties. These can be used to determine protein stability and are quite useful for *in silico* protein analysis to improve function and thermostability.

Keywords: *In silico*, Molecular dynamics, Mutagenesis, Protein thermostability, Rational design.

1. INTRODUCTION

Proteins are remarkable biomolecules. By utilizing a limited set of monomers (amino acids), the resulting variety of structure and function is extraordinary. Proteins are central to cellular processes, including catalysis, formation of cellular structures, storage, transport, communication, energy metabolism, movement, and flow of biological information.

Thermophiles are organisms that grow at temperatures exceeding 50°C. Hyperthermophiles grow at even higher temperatures. Many of them grow at temperatures close to the boiling point of water. Many industrial processes involving enzymatic reactions take place at high temperatures. So, enzymes from

* Corresponding author Syed Farhat Ali: School of Life Sciences, Forman Christian College (A Chartered University), Lahore, Pakistan; Tel: +92-42-99231581; E-mail: farhatali@fccollege.edu.pk

mesophiles are not suitable for these high temperature-requiring processes. In order to improve the efficiency of industrial processes, there is a continuing need for enzymes with better properties. Thermophilic enzymes meet this requirement as they are robust and can tolerate high temperatures [1]. Enzymes have applications in foods, detergents, textiles, leather, starch, and other industries. Moreover, protein engineering strategies have been useful in improving the properties of existing enzymes and tailoring them to improve process efficacy [2]. Some important applications of enzymes for industrial processes are shown in Table 1 [2, 3].

Table 1. Applications of some important enzymes.

| Enzymes | Application |
|----------------------------|--|
| Amylase | Baking, paper and pulp, starch processing |
| Starch debranching enzymes | Starch processing, food industries |
| Cellulase | Plant biomass treatment, paper and pulp, biofuel production |
| Invertase | Food industry |
| Lactase | Food industry, lactose-free dairy products |
| Lipase and esterase | Food industry, detergents |
| Pectinase | Food, juice production |
| Peroxidase | Textile |
| Protease | Meat processing, detergents, leather and textile, dairy products |
| DNA polymerase | Polymerase chain reaction (PCR), gene cloning, diagnosis, molecular biology applications |
| Chitinase | Pharmaceutical products |
| Laccase | Bioremediation, detoxification |
| Amidases | Pharmaceutical products |
| Phytase | Feed and food industries |

2. BASIS OF PROTEIN THERMOSTABILITY

During past years, much work has been done to understand protein thermostability. Many thermophilic proteins have been characterized and their structures determined. The proteins from thermophiles are not very different from their mesophilic counterparts in terms of their function. It has been reported that the thermostability of these proteins depends on various types of interactions, including hydrogen bonds, hydrophobic interaction, van der Waals interactions, and ionic interactions [4].

2.1. Electrostatic Interactions

A greater number of charged residues are found on the surface of thermostable proteins [4]. Electrostatic interactions are important for protein stability. Optimization of electrostatic interactions can result in protein stabilization while maintaining its activity [5]. Displacement of water molecules from the enzyme active site can also result in enhancing its activity. Glucanases have water molecules on their active sites, which are removed upon substrate binding. Engineering glucanases to displace water molecules during catalysis can enhance enzyme activity [6].

Electrostatic interactions of charged amino acid residues and the dielectric response of the protein are important factors in governing its thermostability. Proteins from thermophiles have been found to contain a greater number of charged residues on their surface as compared to those from mesophiles. This increasing trend of dielectric constant from mesophilic to thermophilic proteins modulates the thermal stability [7]. It has also been shown that optimizing electrostatic interactions by increasing the number of salt bridges is an important factor for high-temperature tolerance of proteins. The glutamate dehydrogenase from *Pyrococcus furiosus* has a large network of ion pairs formed by 18 charged residues [8]. Similarly, the enzyme lumazine synthase from *Aquifex* has a greater number of ions pairs as compared to corresponding mesophilic enzymes [9]. Also, the DNA polymerase from *Pyrobaculum calidifontis* (*Pca*) was shown to contain a greater number of salt bridges as compared to the ones found in *E. coli* (*Eco*) DNA polymerase [10]. *Pca* DNA polymerase contains a total of 242 charged amino acids. On the other hand, this number in *Eco* DNA polymerase is 193. A comparison of structures of these DNA polymerases is given in Fig. (1), demonstrating the association of electrostatic interactions with protein thermostability.




Fig. (1). Structures of **A)** *Pca* DNA polymerase – cyan (PDB ID: 5MDN) and **B)** *Eco* DNA Polymerase – green (PDB ID: 1Q8I). Charged residues are shown in red color in both structures. *Pca* DNA polymerase has a greater number of charged residues, resulting in more salt bridges, and is a thermostable enzyme. (The figure is generated in PyMol by using indicated PDB structures).

CHAPTER 4**Pan-Proteomics to Analyze the Functional Complexity of Organisms**

Muhammad Tahir ul Qamar^{1,2}, Barira Zahid³, Fatima Khalid³, Anam Naz⁴, Jia-Ming Song^{1,2}, Sajjad Ahmad⁵, Xitong Zhu², Feng Xing⁶, Muhammad Sarwar Khan⁷ and Ling-Ling Chen^{1,2,*}

¹ State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, College of Life Science and Technology, Guangxi University, Nanning, P.R. China

² Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, P.R. China

³ Key Laboratory of Horticultural Plant Biology (Ministry of Education), College of Horticulture and Forestry, Huazhong Agricultural University, Wuhan, P.R. China

⁴ Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Lahore, Pakistan

⁵ Department of Health and Biological Sciences, Abasyn University, Peshawar, Pakistan

⁶ College of Life Science, Xinyang Normal University, Xinyang 464000, P.R. China

⁷ Center of Agricultural Biochemistry and Biotechnology, University of Agriculture, Faisalabad, Pakistan

Abstract: Proteomics is rapidly expanding with the advent of high throughput technologies and offers a greater understanding of the complexity of life and the process of evolution. Protein profile comparison between genetically heterogeneous individuals may provide important insights into physiological diversity and function. A new term, pan-proteomics, has also been introduced that permits the qualitative and quantitative comparison of proteomes of genetically heterogeneous organisms. Here in this chapter, various aspects of pan-proteomics along with its basic methodology and applications have been discussed.

Keywords: Bioinformatics, Comparative proteomics, Proteomics, Pan-Proteomics.

* **Corresponding author Ling-Ling Chen:** State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, College of Life Science and Technology, Guangxi University, Nanning, P. R. China; Tel: +8618971629380; E-mail: llchen@gxu.edu.cn; ORCID: <https://orcid.org/0000-0002-3005-526X>

1. INTRODUCTION

Proteins are a quintessential part of all living organisms, with different functions essential for life. The word “proteome” was first coined in 1994 by Mark Wilkins. Proteomics is the large-scale protein structure and function analysis [1]. Major advances in molecular biology techniques providing new insights into the nature of genes and proteins are due to the staggering number of genomic projects performed over the past decade. However, many types of information cannot be obtained, and it is impossible to interpret the mechanism of disease and the effect of the environment solely by these results. In this context, to characterize the protein modifications, large-scale study of proteins is inevitable. Proteomics is a large-scale analysis of the whole set of proteins expressed by a cell, tissue, or organism, resulting in an information-rich landscape of expressed proteins and their modulations under a defined set of conditions. Unlike the previous studies of individual proteins or simple macromolecular complexes, proteomics offers a more comprehensive and systematic understanding of biological systems [2, 3].

Proteomics allows evaluating different cellular processes by providing a comprehensive qualitative and quantitative description of protein contents in a cell. Quantitative proteomics provided several valuable insights into proteomes, and it can be further classified in global proteome analysis and relative quantification [4]. Global proteomics strategies are often used for the absolute quantification of one or more proteins in a given sample. On the other hand, relative quantification of two samples with two different physiological states provides insights into the cellular and molecular mechanisms involved in a biological process. Quantification of mRNA content can confirm the presence of protein and its quantity in a cell [5, 6]. This concept allows the comparative analysis of protein measurements on a whole-genome level. So, the protein’s detected differences can enable new insights into the processes accountable for a detected phenotype [7].

Recent technological advances in proteomics have greatly propelled our knowledge about drug development, host-pathogen interaction, and human or animal health. Proteomics offers the ability to interpret the physiological diversity and functions in a complex system. Many of the proteomes of genetically heterozygous organisms may fail to account for underlying genetic variance when compared. Therefore, recent knowledge concerning the functional heterogeneity of individuals at the protein level may be inaccurate or incomplete. To address this, there is a need to consider the impact of genetic heterogeneity on proteome comparisons more significantly. Pan-proteomics is the possible solution here that allows the qualitative and quantitative comparison between genetically heterogeneous organisms [7]. The aim of this chapter is to briefly explain the

concept of pan-proteomics and its applications in different areas of basic life sciences. In addition, proteomics strategies and bioinformatics approaches developed to increase pan-proteomic power have also been discussed.

2. CONCEPT OF PAN-PROTEOMICS

Pan-proteomics is an emerging analytical approach to compare proteome variability within genetically heterogeneous organisms across species of interest [7]. Like the pan-genome, the pan-proteome also refers to the full set of non-redundant proteins thought to be expressed within members of the same species. Similarly, it can be categorized into core proteome (proteins present in all members) and variable or dispensable proteome (proteins present only in some members). The pan-proteomics complements both pan-genomics [8, 9] and pan-transcriptomics [10, 11], which helps to identify genetic variants and the presence of homologous sequences of an organism at the protein level [12, 13]. Comparative proteomic analysis of different individuals of the same species can reveal relationships and genetic variations among individuals without assessing the genomic data [14, 15].

3. APPROACHES AND SOFTWARE USED FOR PAN-PROTEOMICS

Proteomics relies on three fundamental technological cornerstones that include, Mass Spectrometry (MS) to obtain the data essential for individual protein identification; a method to separate complex proteins; and bioinformatics to analyze and assemble the MS data [16]. Just like proteomics, some steps are considered important in pan-proteomics as well, including (i) sample preparation – considering the type of protein fraction and selection of extraction buffer based on different physical-chemical properties of proteins; (ii) identification method – implementation of high-performance methodologies like MudPIT for maximum proteome coverage and dynamic range; (iii) protein sequence database – with the proteome of all species utilized in the study and curated protein sequences. So, the pan-database will contain reference proteome and unique sequences that are not present in the reference proteome [17, 18]. Once a pan-database has been constructed, sequence homology clusters can be inferred from it [7]. In this regard, different methods of homology cluster inference are available or have been reported, including: BLASTclust [19], orthoMCL [20], PipeAlign [21], OrthoFinder [22], CD-HIT [23] and OrthoVenn [24]. In addition, GROMACS [25] can be used for protein's structural clustering confirmations analysis [26]. Once inferred, clusters can be further classified into core, dispensable and species-specific categories. Proteomic data is usually explored with the help of gene ontology (GO) and pathway analysis [7]. Several platforms are available for such

CHAPTER 5

Functional Characterization of Proteins and Peptides Using Computational Approaches

Zeshan Haider^{1,2} and Adnan K. Niazi^{1,*}

¹ Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture Faisalabad, Faisalabad, 38040, Pakistan

² State Key Laboratory of Grassland Agro-Ecosystems, College of Pastoral Agriculture Science and Technology, Lanzhou University, Lanzhou, China

Abstract: Bioinformatics tools have produced enormous data in different repositories over the past decade, which is of great interest today for *in-silico* analysis. Proteins contain one or more peptides that are essential molecules having biological and biomedical functions. Instead of working with sequences, proteomics, and peptidomics, researchers now concentrate more on molecules' processes and metabolic interactions in which proteins or peptides are involved. As a preliminary assessment of possible biological roles, bioinformatics methods are an essential step and greatly reduce experimental verification time and cost. This chapter offers a brief overview of computational methods for predicting the biological features of peptides and proteins. Algorithms using structural, evolutionary, or statistical patterns and strategies based on molecular docking are considered based on machine learning techniques, which are the most common today. The protein and bioactive peptide databases are reported, providing the knowledge required to develop new algorithms. The biological functions for forecasting, the features of proteins, and peptides should be considered, based on the possibility of concluding their natural role. The report includes a list of online resources that researchers can use to evaluate possible protein function and peptides.

Keywords: Bioinformatics, Biological functions, Databases, Machine learning, Molecular docking, Peptides and protein.

1. INTRODUCTION

Proteomics, including peptidomics, is one of the most rapidly developing areas of biochemistry nowadays. These science branches study the totality of proteins and protein fragments (peptides), their functions, and interactions in living organisms [1 - 3]. Mass spectrometry, various electrophoretic approaches, and liquid chro-

* Corresponding author Adnan K. Niazi: Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture Faisalabad, Faisalabad, 38040, Pakistan; E-mail: niazi@uaf.edu.pk, adnan1753@yahoo.com

matography are the primary study methods in proteomics and peptidomics [3 - 5]. To classify and further analyze peptides revealed by mass spectrometry, special algorithms are commonly used. The data obtained allow peptide abundance analysis in different samples (comparative peptidomics), determine the position of a peptide in a protein sequence, elucidate the proteases involved in peptide generation, and predict the structures and functions of the peptide [6]. One of such studies' potential objectives is to look for and evaluate bioactive peptides that, by binding to particular receptors or other targets, modulate physiological functions [7]. In higher organisms like a human, bioactive peptides can affect almost all systems. Antithrombotic peptides play a significant role in inhibiting platelet aggregation and fibrinogen binding, hypotensive peptides that inhibit angiotensin-transforming enzymes and antioxidant peptides that can scavenge free radicals (produced as by-products of cell oxidative metabolism) and inhibit lipid peroxidation are influenced by the cardiovascular system [8, 9]. Such peptides bind the cell surfaces of bacteria and thus inhibit the work of membranes or kill bacterial biofilms. In addition, certain peptides have an antiviral activity or antifungal activity [10].

Technological advances in DNA sequencing have made whole-genome sequencing a hot topic of current research. However, scientists' key challenges regarding sequence data entry are to elucidate the role of proteins and large-scale analysis of entire proteomes (the protein component of genomes) rapidly and accurately. Many local databases exist, *i.e.*, UniProtKB, GenBank, RefSeq and TPA, and Swissport, PIR, PRF, and PDB that record the processed protein sequences [11]. To equate a target sequence to those of known functions, scientists typically use sequence similarity searches. Still, this approach has its drawbacks and depends on the precision of the remaining data offered to date. Protein signatures are used in alternative strategies for the classification of proteins. Some common databases that establish diagnostic protein signatures have emerged for recognized protein families or domains. Each of these databases has its methodology, signature generation parameters, and methods.

As a consequence, it also has strengths and shortcomings of its own [12]. *In-silico* draws on the techniques of bioinformatics to classify proteins and peptides. It offers references to protein and peptide databases. It works on strategies to develop algorithms to study proteins and peptides that would be of interest to specialists working in the field.

2. *IN-SILICO* ANALYSIS OF PEPTIDES

Peptides are biochemical compounds present in nature. In all living species, peptides are present naturally and play a key role in all biological activities, and are synthesized by DNA transcription, like proteins [13 - 15].

There are only 20 amino acids that can be mixed into a lot of diverse molecules. If the molecule is 2 to 50 amino acids in length, is a peptide, or is a longer chain of more than 50 amino acids, it is commonly referred to as a protein. For peptide toxicity, *in-silico* based databases and peptide sequence analysis tools have been developed, which have revolutionized peptidomics.

2.1. Classification and Databases of Peptides

Peptides are deemed to be appropriate resources in different biological fields. They can be used mainly for the rational design of molecules that are bioactive. In the manufacture of targeted drugs and diagnostics, vaccine production, or agriculture, they may be used as ligands. You can classify peptides into two broad structural classes: linear peptides and cyclic peptides. A special type of macrocyclic ring polypeptides, monocyclic peptides, exhibit advantages such as more selective binding and target receptor absorption and greater efficiency and stability compared to rectilinear forms [16]. There are many different online databases and tools available to retrieve the different types of peptides sequences. Such databases and tools are listed below in Table 1.

SECTION II: Molecular Pharming for Human Beings

CHAPTER 6**Molecular Pharming: Research, Developments and Future Perspective****Muhammad Sarwar Khan^{1,*}, Ghulam Mustafa¹ and Faiz Ahmad Joyia¹**¹ *Centre of Agricultural Biochemistry & Biotechnology (CABB), University of Agriculture, Faisalabad, Pakistan*

Abstract: Plants are tamed to function as production factories of pharmaceuticals. Recently, several pharmaceuticals, including therapeutics, drugs, vaccines, vitamins, antibiotics, nutraceuticals, and diagnostic molecules, have been produced through these green factories. Compared with conventional systems, for example, bacterial, yeast, fungal, and mammalian cell cultures, plants are accepted as a cost-effective source of pharmaceuticals products. Considering plants as a versatile, cost-effective, and robust production platform, the system could be exploited in different ways like plant cell culture, transient expression and harvesting, and stable transgenics. This chapter highlights the importance and potential of molecular pharming with special emphasis on methodological aspects, proving the suitability of plants as the most appropriate biopharmaceutical production platform with recent interventions.

Keywords: Biopharmaceuticals, Cell culture, Cost-effective, Plant expression system, Recent innovations.

1. INTRODUCTION

Biopharmaceuticals are biomolecules produced using biotechnological processes. These are protein or nucleic acid-based substances used for therapeutic or diagnostic purposes [1]. Pharmaceutical technology will continue to provide breakthroughs in medical research, leading to the effective treatment of noxious diseases including AIDS, cancer, asthma, Parkinson's, and Alzheimer's diseases [2]. Plant-derived pharmaceuticals have drawn special attention in this context owing to certain salient advantages of this production system as compared with others.

* **Corresponding author Faiz Ahmad Joyia:** Centre of Agricultural Biochemistry & Biotechnology (CABB), University of Agriculture, Faisalabad, Pakistan; E-mail: faizahmad1980@gmail.com

The pharmaceutical market of recombinant proteins is growing steadily, with almost all major pharmaceutical firms reporting a rising share of these products. These pharmaceuticals are usually produced using mammalian or bacterial cell-based processes that are complex to operate and potentially susceptible to human pathogen contamination [3]. Current good manufacturing practice (cGMP) compliant manufacturing facilities require tremendous capital investment and include substantial financial risk. Plant biotechnology can solve some of these drawbacks, but before this emerging industry can compete successfully in the pharmaceutical market, many obstacles remain to be addressed. A variety of different technologies are now operated by plant biotechnology for recombinant protein expression. These developments constitute opportunities in the sector for current and future commercial enterprises [4].

The idea of using plants for the production of recombinant pharmaceutical proteins, known as plant molecular pharming (PMF) or pharmacy (PMP), is not new. The 1st plant-derived recombinant therapeutic protein was human growth hormone, initially developed in tobacco and sunflower in 1986 [5]. The HBs Ag (hepatitis B surface antigen) was later expressed in transgenic tobacco. Physically and antigenically, this plant-derived antigen was identical to HBs Ag obtained from recombinant yeast and human serum. HBs Ag derived from yeast is clinically used for vaccination against HBV. It has been reported that above 100 recombinant proteins were expressed and produced through a plant-based expression system [6].

The basic term ‘ATMPs (advanced therapy medicinal products)’ is used by the European Medicine Agency (EMA) to refer to human medicines that are based on tissue, cells, and gene engineering. Cell therapy products (CTPs) are cells/tissues containing biomedicines that have been manipulated to modify their biological properties and can be used to cure, prevent, or diagnose diseases. The common benefits of these systems are ease of manipulation, low cost, speed, and high protein yield.

The developments in functional genomics and recombinant DNA technology have been merged to provide vast opportunities for the cost-effective production of commercial-scale recombinant protein. Enzymes are now widely used in industry for bio-catalytic reactions, allowing them to be used in anything from cultivation and bioremediation to medicine and food preparation. The rise of the biopharmaceutical industry has been brought about by further exploitation and modifications in the recombinant protein structure and function for therapeutic uses [7]. Any of the therapeutic proteins, including growth hormones, pancreatic enzymes, can now be produced from alternative sources, thus available to the ultimate consumer in natural form. Further, advancements in recombinant DNA

technology have refined it by making possible the isolation and expression of protein-coding genes in the transgenic host cells. Transgenic sources of these recombinant proteins pave the way to the production of low-cost proteins with increased protection and efficiency [8].

2. HISTORY OF THE BIOPHARMACEUTICAL INDUSTRY

Proteins of mammalian origin have been produced in plants since the late 1980s. Since then, ‘molecular plant farming’ has widely been exploited to use plants as protein factories. Fisher introduced the concept of molecular pharming (biopharming) and highlighted that any mammalian protein, including vaccines, blood proteins, antibodies, and medicinal therapeutics, can effectively be produced in plants [9]. Over the past century, vaccine production has progressed tremendously. The burden of many life-threatening diseases has been minimized by traditional vaccines. Alternative approaches have been employed for the development of novel vaccines with the ability to effectively protect against new diseases [10, 11].

Three key groups had been striving to ascertain the notion of vaccine production in plants under the leadership of Charles Arntzen, Roy Curtsis, and Hilary Koprowski. Arntzen’s research contributed first peer-reviewed publication in the area of plant molecular farming [12]. It was suggested that an edible vaccine is a fruit or vegetable with a particular antigen that can be delivered cost-effectively with increased efficacy. This proved the worth of plants as an alternative source of vaccine having the ability to compete with the existing market. Thus, using plants as edible vaccines could be an effective alternative to treat infectious diseases. The beauty of this concept was that recombinant plants could be grown near to the target population, facilitating the availability of inexpensive and effective vaccines. The reduced cost of downstream processes, transportation, and purification would result in reducing the cost as compared with traditional vaccines. Despite several advantages, there are certain limitations as well, including optimization of dosage and contamination of the food chain by producing recombinant plants [13].

Dow Agro Sciences LLC announced (on 31st January 2006) to be the global leader and obtained the World’s first regulatory approval from USDA. The approved plant-based vaccine could combat the ND (Newcastle Disease). The vaccine antigen was expressed in tobacco plant cell lines through suspension culture in a traditional bioreactor system. The resulting cells were extracted and minimally processed for the final formulation of the vaccine [14, 15].

Green Factories: Plants As A Platform For Cost-effective Production of High-value Targets

Muhammad Omar Khan^{1,2}, Ayesha Siddiqui^{1,2} and Niaz Ahmad^{1,2,*}

¹ Agricultural Biotechnology Division, National Institute for Biotechnology & Genetic Engineering (NIBGE), Jhang Road, Faisalabad, 38000, Pakistan

² Department of Biotechnology, Pakistan Institute of Engineering and Applied Sciences (PIEAS), Nilore, Islamabad, Pakistan

Abstract: Transgenic plants have been developed since the early 1980s, when researchers were able to transform a piece of foreign DNA into a plant genome. Since then, the technology has expanded enormously, giving rise to many private and public ventures in the field of plant-based recombinant technology. The technology has helped in crop improvement against various biotic and abiotic stresses such as insect resistance and herbicide tolerance, as well as improving their nutritional values, for example, Golden rice. In addition to crop improvement, the technology has enabled plants to be used as green factories for the production of recombinant proteins. Several platforms are available for the heterologous expression of foreign proteins, each of which represents its own set of advantages and limitations. Plants offer many advantages for inexpensive yet large-scale production of high-value targets, making them extremely attractive for commercial applications. In this chapter, we briefly discuss the need for using plants as solar-powered cellular factories to produce recombinant proteins. We provide a snapshot of different expression systems and argue that the plant-based expression system is highly commercially feasible not only for the production of high-value targets but also to help address global challenges like Covid-19.

Keywords: Biopharming, High-Value targets, Green factories, Plants.

1. WHY PLANT-BASED EXPRESSION SYSTEMS?

Heterologous expression of recombinant proteins for different applications has become a focus of intensive research for a while, paving the way for another revolution in the area for the development of new production technologies. The demand for cost-effective yet large-scale production of protein and secondary metabolites for various purposes, such as medical reagents, cosmetic products,

* Corresponding authors Niaz Ahmad: Agricultural Biotechnology Division, National Institute for Biotechnology & Genetic Engineering (NIBGE), Jhang Road, Faisalabad, Department of Biotechnology, Pakistan Institute of Engineering and Applied Sciences, (PIEAS), Nilore, Islamabad, Pakistan; E-mail: niazbloch@yahoo.com

and industrial enzymes, in terms of quantity, diversity, and, most importantly, quality has dramatically increased since the past decade [1]. The gap between demand and supply has further increased due to inefficient yet highly expensive production systems [2, 3]. Several systems, including bacteria, yeasts, animal cells, transgenic animals, plant cells, and transgenic plants, are available for the heterologous production of high-value targets [4, 5]. All available expression systems have their pros and cons in terms of cost, time, efficiency, product size, growth conditions, yield, post-translational modification, downstream processing, and regulatory approval [6]. The advantages of plant expression platforms are cited in several earlier reports [7 - 12]. Table 1 shows head-to-head comparisons of all existing platforms. Transgenic plants have become a focus of interest as new generation bioreactors mainly due to: i) reduced up-front production costs, ii) lower risk of endotoxins as well as human pathogen contamination, iii) scalability, iv) availability of existing infrastructure for the cultivation of transgenic plants, v) assemble complex protein with eukaryotic-like post-transcriptional modifications. However, plants lack the human-like N-glycosylation mechanism for protein processing that has been overcome by engineering tactics to ensure the authentic quality, homogeneity, and quantity [13]

Table 1. Comparison of different expression system [10].

| Parameter | Bacteria | Yeast | Insect cells | Microalgae | Mammalian Cells | Transgenic Plants |
|-----------------------|----------|---------------|--------------|----------------------------|-----------------|----------------------------|
| Capital cost | Medium | Medium | High | Medium | Very high | Low |
| Operating cost | Low | Medium | High | Low | Very high | Low |
| Production scale | Short | Short | Medium | Short | Long | Long |
| Speed | Fast | Fast | Medium | Fast | Slow | Slow |
| Multigene engineering | Yes | No | No | Yes | No | Yes |
| Glycosylation | Absent | Incorrect | Yes | Yes, absent in chloroplast | Yes | Yes, absent in chloroplast |
| Contamination risk | High | Medium | High | Low | High | Low |
| Multimeric assembly | No | No | No | Yes | No | Yes |
| Protein folding | Low | Medium | High | High | High | High |
| Protein yield | High | Moderate high | Medium | High | Medium | Low-High |
| Scale up cost | High | High | Very high | Medium | Very high | Very low |
| Safety | Low | Unknown | Medium | | Low | High |

(Table 3) cont....

| Parameter | Bacteria | Yeast | Insect cells | Microalgae | Mammalian Cells | Transgenic Plants |
|--------------|------------|----------|--------------|------------|-----------------|-------------------|
| Storage | Very cheap | Costly | Expensive | Low | Very expensive | Very cheap |
| Distribution | Easy | Feasible | Difficult | Easy | Difficult | Easy |

Plant molecular farming (PMF) is termed as the technique of producing high-value proteins recombinantly in plants without disturbing their phenotype, metabolism, or performance. The proteins have been produced by this technique for more than 30 years, either in purified form, crude extract, or in planta [3, 14]. The idea of molecular farming based on the genetic transformation of plants was first proposed in the 1980s [15], which has now become a reality and is often termed as the 3rd generation of biotechnology [6]. The first examples of molecular farming using transgenic plants and plant cell suspension cultures involved the production of a human growth hormone, Nopaline synthase [16], and an antibody IgG₁ (6D4) [17]. However, the commercial application of this platform came years later when avidin was recombinantly produced in transgenic maize [18]. The breakthrough to commercial success for plant-derived biologics culminated in 2012 when the first plant-made pharmaceutical, Taliglucerase alfa, commercially known as Elelyso[®], was developed by Protalix BioTherapeutics, was approved by the US Food and Drug Administration [19]. Elelyso[®] is a recombinant human glucocerebrosidase used for the treatment of Gaucher's disease (lysosomal storage disorder) [20].

The use of plants for the production of valuable proteins has been refined and improved over the years due to advancements in knowledge and technology. This has led to a major paradigm shift in the pharma sector, as the potential drawbacks associated with the early stages of PMF, including high expression level and efficient downstream processes, have been attained [6]. The product portfolio ranges from pharmaceutical therapeutics to non-pharmaceutical products such as antibodies, vaccine antigens, enzymes, growth factors, research or diagnostic reagents, and cosmetic ingredients. A number of 'proof-of-concept' studies have been performed to evaluate the potential of different plant species as hosts for molecular pharming [21, 22]. The host cells or the plant used for molecular farming purposes, depending upon target protein and its application, range from crop plants (rice, maize, tobacco, alfalfa, safflower, and lettuce) to pondweed, algae, microalgae, and mosses. The *Nicotiana* genus has been widely used for genetic transformation studies as it is easily genetically manipulated and has a fast growth rate. Two species, *Nicotiana benthamiana* and *Nicotiana tabacum* are considered as 'biological warehouses' for the production of many pharma or non-pharma products by the stable and transient expression [21]. Many plant-based

CHAPTER 8

Analysis of Cross-Reactivity, Specificity and the Use of Optimised ELISA for Rapid Detection of *Fusarium* Spp.**Phetole Mangena^{1,*} and Phumzile Mkhize²**¹ Department of Biodiversity, School of Molecular and Life Sciences, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, Republic of South Africa² Department of Microbiology, Biochemistry and Biotechnology, School of Molecular and Life Sciences, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, Republic of South Africa

Abstract: Many strides have been made in the development of antibody-based detection systems for rapid and sensitive analysis of *Fusarium* pathogens and their toxins. Antibody cross-reactivity, specificity, and binding affinity with antigenic molecules affect the efficacy in which these molecules serve their own functions. Researchers are, therefore, directed in investigating the principles that govern cross-reactivity, specificity, and the relationship between them, using various tools such as optimised ELISA. This is important because the ability of *Fusarium* spp. to infect and produce mycotoxins in agronomic crops passes these toxins to animals and humans after contact or ingestion. Antibodies that recognise and bind particular antigens with great affinity and specificity, especially for the effective relief of unwanted *Fusarium* pathogenic materials in humans and animals, are thus required. Furthermore, the demand for fungal contaminants free agriculture, emerging antifungal drug resistance, and the fatal health effects of fungal infections in immunocompromised humans and animals drive the need for the development of a rapid, sensitive, reliable, and accurate relief system for these pathogens. Therefore, this chapter provides a succinct review on the role of antibody cross-reactivity and specificity, with reference to basic principles, challenges, and detection for rapid and reliable assessment in *Fusarium* pathogens.

Keywords: Antibody specificity, Antigens, Cross-reactivity, ELISA, *Fusarium*, Immunoglobulins, Mycotoxins, Somatic hypermutation.

* **Corresponding author Phetole Mangena:** Department of Biodiversity, School of Molecular and Life Sciences, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, Republic of South Africa; Tel: 015-268-4715; E-mail: Phetole.Mangena@ul.ac.za

1. INTRODUCTION

The genus *Fusarium* contains a group of filamentous fungi commonly found in soils, in which its species are linked with animal and plant pathogenesis. *Fusarium* species are toxigenic, and the mycotoxins (*i.e.*, compounds with deleterious effects on susceptible host organisms) produced by these fungi are often associated with animal and human infections, including some of the diseases affecting seedlings and mature plants. According to Moretti [1], these organisms remain among some of the widely occurring plant-pathogenic species, causing diseases in several agriculturally important crops, particularly cereals, lumber, and pulses. Many of *Fusarium* spp. produce a wide range of biologically active secondary metabolites (Table 1), with tremendous accompanying chemical diversity. Some of the bioactive metabolites serve as products of primary and secondary metabolic value, characterised by a distinct and unusual chemical structure with varying molecular weights.

Table 1. Brief outline of mycotoxins and valuable compounds produced by *Fusarium* spp., including the early and recently discovered examples of bioactive compounds.

| Fungal spp. | Mycotoxins/ SMs | Brief Description | References |
|-----------------------------------|------------------------|---|---------------------------------|
| <i>F. sambucinum</i> TE-6L | Indole alkaloids | Amoenamide C and Sclerotiamide B, from angularly prenylated indole alkaloids with pyrano [2,3-g] indole moieties <i>Application:</i> Antimicrobial and insecticidal activity | Zhang <i>et al.</i> [4] |
| Unclassified <i>Fusarium</i> spp. | Terpenes | Orcyl aldehyde units (condensed with farnesyl side chain terminally cyclised to cyclohexanone ring in γ , ϵ , δ , ζ , α and β) designated LL-Z1272 <i>Application:</i> anti- <i>Tetrahymena pyriformis</i> activity | Ellestad <i>et al.</i> [13] |
| <i>F. fujikuroi</i> | Polyketides | Yellow and/ orange pigmented fusarins, encoded by a <i>fusA</i> gene <i>Application:</i> Antimicrobial activity | Diaz-Sanchez <i>et al.</i> [14] |
| <i>F. graminearum</i> | Non-ribosomal peptides | Fasaotaxin A, product of ectopic expression of <i>fg3_54</i> gene cluster <i>Role:</i> A as a virulence factor required for cell-to-cell invasion of wheat by <i>F. graminearum</i> | Jia <i>et al.</i> [15] |
| <i>F. incarnatum-equiseti</i> | PKs + NRPs derived | Polyketides (PKs) and Nonribosomal peptides (NRPs) secondary metabolites synthesized by NRP synthetase and type-1 PK synthase <i>e.g.</i> Carotenoid, fusarubin pigment, enniatin, fusarin and zearalenone mycotoxins | Villani <i>et al.</i> [16] |

(Table 3) cont....

| Fungal spp. | Mycotoxins/ SMs | Brief Description | References |
|---|-----------------|--|---|
| <i>F. crookwellense</i> , <i>F. culmorum</i> and <i>F. graminearum</i> | Trichothecenes | Nivalenol (NIV), deoxynivalenol (DON) or scirpentriol (STO) chemotypes | Lauren <i>et al.</i> [17] |
| <i>F. oxysporum</i> , <i>F. proliferatum</i> , <i>F. moniliforme</i> and <i>F. nygami</i> | Fumonisin | Fumonisin A (N-acetyl analogs, FAs), B (sphingosine N-acyltransferase, ceramide synthase), C (dimethyl analogs, FCs) and P (N-3-hydroxypyridinium analogs, FPs) | Sewran <i>et al.</i> [8], Tamura <i>et al.</i> [9] and Rheeder <i>et al.</i> [10] |
| <i>F. graminearum</i> , <i>F. culmorum</i> and <i>F. crookwellense</i> | Zearalenone | Zearalenone (ZAN), α -zearalenol (α -ZOL), β -zearalenol (β -ZOL), α -zearalanol (α -ZAL) and β -zearalanol (β -ZAL) | Tian <i>et al.</i> [11] |
| <i>F. proliferatum</i> , <i>F. solani</i> and <i>F. pseudonygamai</i> | Fusaproliferin | Fusaproliferin, a sesterterpene mycotoxin C ₂₀ -core carbon skeleton possessing an extra C ₅ -head/C ₅ -tail unit | Fotso <i>et al.</i> [18] and Liuzzi <i>et al.</i> [19] |
| <i>F. concentricum</i> | Beauvericin | Structurally related beauvericin (BEA) and enniatins B (ENN B) synthesised by multifunctional enzyme enniatin synthetase containing both peptide synthetase and S-adenosyl-L-methionine-dependent N-methyltransferase activities | Liuzzi <i>et al.</i> [19] |
| <i>F. Orthoceras</i> var. <i>enniatinum</i> | Enniatins | Structurally related beauvericin (BEA) and enniatins B (ENN B) synthesised by multifunctional enzyme enniatin synthetase containing both peptide synthetase and S-adenosyl-L-methionine-dependent N-methyltransferase activities | Liuzzi <i>et al.</i> [19] |
| <i>F. proliferatum</i> , <i>F. phyllophilum</i> and <i>F. subglutinans</i> | Moniliformin | Small ionic carboxylate potassium/ sodium salt (1-hydroxycyclobut-1-ene-3,4 dione) with a highly toxic one water crystallisation | Fotso <i>et al.</i> [18] |
| Note: SMs- Secondary metabolites Spp. – species | | | |

Not only are mycotoxins produced by species in this genus, but some secondary metabolites potentially serve as a source of many useful novel compounds with enzymatic capability, antibacterial activity, antiviral, anti-parasitic, and growth-promoting effects, as well as other properties can be obtained [2, 3]. *Fusarium* could, furthermore, be used in industrial processing to directly or indirectly provide enzymes used to catalyse the generation of various other novel substances such as pigments, cosmetic and food compounds that may be used to substitute synthetic compounds [2, 4]. These compounds indicated in Table 1 provide the basis for developing new promising and prolific sources of bioactive secondary metabolites with prominent biotechnological applications, as well as the detection

Plant Molecular Pharming For Human Diseases

Kiran Saba¹, Muhammad Suleman Malik¹, Sara Latif¹, Fatima Ijaz¹,
Muhammad Sameeullah² and Mohammad Tahir Waheed^{1,*}

¹ Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, 45320, Islamabad, Pakistan

² Innovative Food Technologies Development Application and Research Center, Faculty of Engineering, Bolu Abant Izzet Baysal University, 14030, Bolu, Turkey

Abstract: Infectious diseases pose an increasing threat to global health. The world has experienced many outbreaks due to Emerging Infectious Diseases (EIDs) in the 21st century. Vaccination proves to be the most successful public health intervention to counter such outbreaks. Vaccines against many diseases are available. Most of these vaccines either consist of live or attenuated strains, thus posing health risks. There is a need for new and safe vaccines to prevent and mitigate the impact of outbreaks due to emerging and endemic infectious diseases. The requisition of plant-based medicine is increasing day by day because of their non-toxic nature with no to very few side effects and readily available at a reasonable cost. In the present chapter, we will discuss the importance of plant molecular pharming (PMP) with its perspective on human diseases. Several advantages of PMP in relation to the United Nations' sustainable development goals (SDGs) will also be deliberated.

Keywords: COVID-19, Human diseases, Plant molecular pharming, Sustainable development goals, World health organization.

1. INTRODUCTION

Kingdom Plantae is a huge source of biologically active molecules and compounds and it is the biggest known source of medicines since pre-historic times. According to the oldest available record (5000-3000 BCE by Sumerians on clay tablets), humans understood diseases and the use of medicines to cure their ailments [1]. Independent of each other, all big ancient civilizations such as China, Greece, and the Arab developed their medical systems, but all of them

* Correspondence author **Mohammad Tahir Waheed:** Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, 45320, Islamabad, Pakistan; E-mail: tahirwaheed@qau.edu.pk

primarily depended on plants and plant-derived components [2]. To fight against natural selection pressure, human beings always turned to the plants, either to make them a source of food or to fight against pandemics. Along with the bigger civilizations, the smaller communities in Asia, Africa, and Latin America have a known history of reliance on traditional medicaments that are largely based on plants for prompt access to a rather safe, cost-effective, competent, and culturally acceptable solution to the primary health care [3].

Since ancient times, people around the world have relied primarily on plants to fulfill all their medicinal needs, for alleviating ailments, and discovering a cure to relieve pain and discomfort. The early man was encouraged to explore his immediate natural environment and try many plant and animal products, minerals, and a range of therapeutic agents [4]. Plants play an appealing role in the modulation of human and non-human diseases [5]. More than 75% of the medicines to control infectious diseases are of plant origin, whereas about 61% of the drugs approved by the FDA are either isolated completely from plants or are the derivative of plant-based active compounds. Not only in primitive times, but plants are also still the best source of food and medicine [6]. According to the World Health organization (WHO), about 80% of the population of the developed and developing countries believes in traditional medicines or plant-derived drugs for their primary health needs [7]. The era of pharmaceutical sciences and industries is well developed now and growing rapidly, and the market is being introduced to a variety of synthetic drugs. The modern pharmacopeia contains at least 25% of drugs that are plant derivatives or semi-synthetic, made up of prototype compounds derived from plants [8]. The requisition of plant-based medicine is increasing day by day because of the flourishing cognizance of natural products, being nontoxic, with few side effects. These are readily available at a reasonable cost and sometimes the only available source of health care available to the poor or low-income communities. Hence, plant-based medical practices hold an imperative spot in the socio-cultural and economic values of both developing and developed countries traditionally [9]. There is an undisputed belief that 'green medicine' is better than synthetic drugs. Since the last decade, an upsurge in the utilization of herbal medicines has been seen even in industrialized countries [10]. It is reported that over 90% of medicinal plants utilized by the pharmaceutical industries are collected in their raw form from natural sources. In about 800 species utilized by industries, less than 20 species of plants are cultivated commercially [11]. Hence, the plant collection for pharmaceutical purposes involves destructive harvesting. This massive harvesting is a big threat to the reservoirs and natural diversity of medicinal plant resources and ultimately to the economy of the country if the biodiversity is not sustainably used. The commercial cultivation of medicinal plants is more appropriate for use in the production of drugs [12].

Molecular pharming presents the best alternative to produce economic modern medicines and ensure their large-scale availability around the globe. Molecular pharming is defined as the synthesis of recombinant pharmaceutical products using plants. The field of plant molecular pharming emerged in the early 1990s as a subdivision of plant biotechnology, and the prime purpose was widely scalable production of recombinant therapeutic proteins at an affordable cost [13]. One of the main characteristics of plant molecular pharming is that it includes diverse platforms and technologies developed with recognizable and overlapping interests, linked only by the utilization of plants as bio-factory. Similarly, it includes plant cells or only the part of plants growing in small containers on the synthetic nutrient media or the plant grown on the soil at a large scale, containing a stably integrated transgene for the expression of recombinant protein [14]. Plant molecular pharming has existed since the successful transformation of the first higher plant in 1983 [15]. The expression of the first human antibodies in the plants was done by Doring [16] and was broadened to express secretory antibodies by Hiatt *et al.* [17]. The first protein (Avidin) expressed in plants for the commercialization purpose was done by Hood *et al.* [18], followed by Aprotinin (used as an anti-inflammatory and wound healing agent), a recombinant pharmaceutical drug [19].

For the last two decades, plant molecular pharming has been resuscitated by the commercialization of biopharmaceutical products. A significant breakthrough was achieved when the first-ever molecular pharming product enzyme taliglucerase alfa was approved for human use in 2012. This was the recombinant form of human glucocerebrosidase designed and developed by Protalix Biotherapeutics® for the treatment of Gaucher's disease, a lysosomal storage disorder [20]. Two more plant-derived pharmaceutical products approved by the European Union were insulin expressed in safflower developed by SemBioSys Genetics and HIV-neutralizing monoclonal antibody expressed in tobacco by a publicly funded consortium (Pharma-Planta; <http://www.pharma-planta.net>). In the production of both recombinant products, the protocols adapted were following the advanced GMP (pharmaceutical good manufacturing practice) [21].

A plant-based system has several advantages, mainly safety and high expression of recombinant proteins [22, 23]. During the Ebola outbreak in 2014, Zmapp (a plant-made monoclonal antibody cocktail) has shown the ability to fight against this disease [24]. The most promising candidates are the influenza vaccines developed by Medicigo Inc. that rely on using a non-replicative vector carrying viral regulatory sequences to mediate the transient expression of Hemagglutinin (HA) in *N. benthamiana*, which has led to injectable vaccine candidates [25, 26]. Recently, functional single-chain monoclonal antibodies are also produced in plant systems, providing simpler molecules for viral neutralization for rabies [27].

Plant Molecular Farming for Human Therapeutics: Recent Advances and Future Prospects

Amna Ramzan¹, Zainab Y. Sandhu², Saba Altaf¹, Aisha Tarar¹, Iqra Arshad¹, Sumera Rashid¹, Huma Shakoor¹, Rabia Abbas¹ and Bushra Rashid^{1,*}

¹ Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan

² Montclair State University, Montclair, New Jersey, NJ 07043, USA

Abstract: Plant molecular farming (PMF) aims to develop plants that express and accumulate proteins of our interest in considerable quantities. Transgenic plants produce edible vaccines, antibodies, therapeutic proteins for human and animal health, and other recombinant proteins required for industrial purposes. Plant systems (PS) to produce pharmaceutical products are preferred over microbial and mammalian systems as they require less input to grow and produce higher biomass. Hence, a variety of proteins are synthesized by plants that are completely free from human pathogens and mammalian toxins. Additionally, they have immunity against infectious and other life-threatening diseases such as cancer. In this review, plant-inferred therapeutic and non-therapeutic protein items that are in the position of clinical progression or commercialization are summarized. Available plant production platforms are also compared along with associated biosafety and regulatory issues. Further, plant transformation techniques are also analyzed for the development of genetically modified organisms in vaccine production. The use of PMF on a commercial scale is still a long way to go before it is achievable. New methods and techniques are needed to be developed to solve the problems of low yield, scalability, stability, and efficacy of the recombinant proteins, as well as biosafety and regulatory issues. Hence, this strategy will be the ultimate proposed solution to protect humans and animals from health threats in the future.

Keywords: Genetic transformation, Plant molecular farming, Pharmaceutical products, Plant systems, Recombinant Proteins, Transient Expression.

* Corresponding author **Bushra Rashid:** Centre of Excellence in Molecular Biology, University of the Punjab Lahore, Pakistan; Tel: +92 42 35293141-6; Ext 142; E-mail: bushra.cemb@pu.edu.pk

1. INTRODUCTION

The production of many useful products and recombinant proteins from genetically modified plants is known as plant molecular farming. The term has many other names such as pharming, plant-made pharmaceuticals, plant bio-pharming, bio-manufacturing, bio-pharmaceuticals, plant-derived products of interest, and plants with novel traits [1]. It is a unique application of genetic engineering as it involves plants to manufacture different valuable proteins at the industrial level. Recombinant DNA technology has made it possible to isolate a gene of interest from any organism and its transformation in the plant expression system to alter the specific trait. A worldwide increase in demand for therapeutic products leads the industries and governments towards an alternative approach of pharmaceutical production, plant systems (PS). This basic research field has global worth in the future [2].

The concept of using genetically modified plants is not recent; it dates back to 1986, when tobacco was genetically modified for the first time to produce a human growth hormone [3]. Human serum albumin is reported to be the second plant-derived product obtained from genetically modified tobacco and sunflower [4]. One big breakthrough in developing the field of PMF was brought about in 2012 when the first plant-derived recombinant protein “taliglucerase alfa”, a recombinant human glucocerebrosidase was synthesized and developed by Protalix Bio-therapeutics. Later on, that was approved for clinical trials for the treatment of Gaucher’s disease. Afterward, many other plant-derived products, such as antibodies, vaccines, enzymes, biocatalysts, biosensors, diagnostic reagents, growth factors, and cosmetic reagents, were commercialized [5].

Several living systems like yeast, bacterial, and animal cell cultures are being used for the production of recombinant proteins. Methods of extraction and purification, along with cold storage, short shelf-lives, and transportation, make these production systems expensive [6, 7]. Plants can be used as “bioreactors” and can replace fermenters, which will reduce the upstream facility and processing of plant tissues for the oral delivery of edible vaccines. This will reduce the downstream processing [8]. The production cost of biological molecules by using plants is less as compared to other systems [9, 10]. Moreover, they also minimize the health risks with additional benefits of high stability of recombinant proteins at large-scale production [11]. The advantage of the production of therapeutically active bio-molecules in edible crops is that they are taken orally as a regular diet, without any hesitation or change in daily habits. It also offers swift scale-up and suitable storage of unprocessed plant materials. The life-threatening diseases and infections in humans and animals due to viruses, bacteria, and other pathogens are now possible to treat with edible vaccines [12, 13]. The availability of cheaper,

easy to consume, and easy to store plant products (seeds, fruits, leaves, *etc.*) that contained edible recombinant proteins, made it possible to prevent life-threatening diseases such as HIV, HBV, *etc.* [14, 15].

Presently, PMF is becoming a very profitable industry with the synthesis of several new recombinant proteins, and many biotechnological companies and governments of different countries are adopting it. Profit associated with PMF can be envisaged by comparing the development of Bt-cotton with that of Bt-corn. An international PMF society has also been formed, and it will become a foundation to support the production of recombinant proteins from PS [16]. In upcoming years, the main focus of scientists will be the development of pharmaceutical products from PS against complex diseases like metabolic disorders, infectious and neurodegenerative diseases and cancer, *etc.* [17].

The current study summarizes the applications and benefits of PMF associated with health issues in humans and animals. It also summarizes available PS, their benefits and limitations, and the solutions to solve these limitations in the future. It also covers health and environmental concerns associated with PMF and different approaches to minimize these limitations so that PMF products may not be rejected by Genetically Modified Organisms' legislation bodies and the general public. Furthermore, it also covers available methods of genetic transformation to develop transgenic plants that synthesize the required proteins on a small as well as on a commercial scale because benefits associated with PMF will only be realized when production is taken up at a commercial scale.

2. SIGNIFICANCE OF PLANT MOLECULAR FARMING (PMF) APPLICATIONS

Several reports have shown benefits associated with PMF in comparison with other production systems [18]. The pattern of protein synthesis in plants is not very much different from the mammalian pattern but plant systems are very cost-effective. Plants also have protein disulfide isomerases and certain chaperons that ensure proper folding and assembly of native as well as non-native proteins and this capability makes them superior over bacterial production platforms [19]. Types of post-transcriptional modifications specifically N- and O- type glycosylation offered by different plant species make PS the most suitable and cost-effective platforms for the synthesis of human-like proteins as well as bio-betters. Such modifications play their role in efficiency, storage as well as downstream processing [20]. Production cost is also reduced to a considerable extent because downstream processing is not required in some cases like edible vaccines and it is also free from human pathogens. Many protein products are

Proteins and Peptides as Biomarkers for Diagnosis of Cardiovascular Diseases

Sehar Aslam¹, Samman Munir¹, Muhammad Shareef Masoud¹, Usman Ali Ashfaq¹, Nazia Nahid¹, Mohsin Khurshid² and Muhammad Qasim^{1,*}

¹ Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan

² Department of Microbiology, Government College University, Faisalabad, Pakistan

Abstract: With the increase in the prevalence of cardiovascular diseases internationally, particularly cardiac failure (CF) and atherosclerosis, the investigation for new biological markers remains one of the main priorities. In contrast to complicated diagnostic methods that might not be appropriate to be employed on a larger population, biological markers are effective for the screening of the population. Owing to their non-invasive detection with typically high accuracy and sensitivity, circulating biomarkers have become increasingly significant for routine medical practice. Cardiac troponins and natriuretic peptides (NPs), specifically brain NP (BNP), mid-regional pro arterial NP, and N-terminal (NT) pro BNP, are validated blood biological markers in the diagnosis of CF and prediction of CF-associated outcomes. Inflammatory proteins like C-reactive protein can also have increased importance in anti-inflammatory treatment guidance. Moreover, next-generation biological markers like galectin-3, growth/differentiation factor 15, diverse miRNAs, and soluble suppression of tumorigenicity-2 might have additional value in the analysis of ventricular remodeling and differentiation of CF subtypes. In this chapter, we will first discuss the biological markers as per the major categories of cardiovascular disease, *i.e.*, myocardial stress, inflammation, plaque instability, myocardial injury, systemic stress, calcium homeostasis, and platelet activation. Lastly, we will describe the multi-marker methods, including various combinations of novel and established biomarkers that may improve the risk prediction of CF at the population level.

Keywords: Acute cardiac infarctions, Cardiovascular diseases (CVD), Cardiac failure (CF), Congenital heart diseases (CHD), Natriuretic peptides (NPs).

1. INTRODUCTION

Cardiovascular disease (CVD) is the leading cause of death internationally, in

* Corresponding author Muhammad Qasim: Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan; E-mail: qasemawan@gmail.com

both developing as well as industrial countries, and involves arteriosclerotic (for example, peripheral arterial disease (PAD), cerebrovascular disease, coronary heart disease (CHD)), and nonarteriosclerotic disease (venous thromboembolism, congenital heart defect (CHD) and valvular disease). The incidence of CVD rises with age, and numerous risk factors, like obesity, alcohol abuse, physical inactivity, and tobacco use, are involved in the progression and development of CVD [1]. Moreover, an additional increase by almost 50% is expected till 2030, thus rising social and economic challenges with cost explosion in the coming decades [2]. The lifetime risk for cardiac failure (CF) is still 20-45 percent and highly age-dependent [3]. The rates of CF hospitalization declined significantly over the years; however, the one-year mortality rate due to CF has not yet substantially improved [4].

One key issue in the development of preventive approaches is that modern risk assessment tools have reduced predictive capacity and undergo miscalibration when employed on various population groups. Biomarkers have been increasingly attracting the scientist, as they enable the non-invasive identification of high-risk patients. The development of unique and highly prognostic CVD biomarkers possesses the potential of improving risk stratification and facilitate the targeted prevention approaches in the pre-clinical phase when treatment would most probably be effective. The use of markers in a clinical setting is also recommended in modern CF guidelines, which indicates their growing importance in the field of CF. Furthermore, circulating markers can provide valuable information regarding causal pathways involved in disease and possess the potential of pathway-targeted treatments and personalized treatment approaches.

This chapter aims to describe both the novel as well as established biological markers in CVD risk assessment. Biological markers will be characterized based on various pathophysiologic processes they indicated and placed within the framework of unmet needs in the area of CVD risk estimation and prevention.

2. BIOMARKERS FOR CVD

A biological marker can perform various functions when utilized within a clinical setting. It is described as a “characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” and performs a variety of functions according to different phases in the evolution of disease (Fig. 1) [5]. Therefore, biomarkers are considered as an indicator of a disease state, disease rate, or disease trait [6]. A biological marker for cardiovascular disease is not restricted to a particular molecule, for example, RNA, metabolite, or protein, measured within a biospecimen like tissue or bodily fluids (cerebrospinal fluids,

urine, plasma), but also a determination of various physical parameters, for example blood pressure, echocardiogram or electrocardiogram.




Fig (1). Characteristics and use of Biomarkers.

Preferably, a CVD biomarker should improve the capability of the clinician to treat the affected patient in the best possible way. Though numerous studies have suggested many protein markers for cardiovascular diseases, only a few of them have been employed successfully within cardiology practice – most of them are used for diagnostic purpose (Table 1).

Table 1. Commonly used diagnostic biomarkers for CVDs.

| Biomarkers | Pathology | References |
|----------------------------------|------------------------|------------|
| Mammary derived growth inhibitor | Critical illness | [114] |
| | Myocardial infarction | [115] |
| Cardiac troponins | Coronary heart disease | [116] |
| | Myocardial infarction | [29] |
| Copeptin | Critical illness | [117] |
| | Myocardial infarction | [118] |
| Atrial natriuretic peptide | Ischemic stroke | [119] |
| Brain natriuretic peptide | Heart failure | [120] |
| Myosin-binding protein-C | Myocardial infarction | [121] |

Biomarkers for cardiovascular disease are usually categorized according to various pathological processes they indicate. As many biological markers reflect numerous pathophysiological processes involving extra-cardiac pathology (for example, kidney failure), this method can result in oversimplification. Yet, to be in accordance with the current research, the cardiac biological markers in this chapter are categorized based on the major classes of CVDs, *i.e.*, myocardial stress, myocardial injury, inflammation, plaque instability, calcium homeostasis,

SECTION III: Molecular Pharming for Animals

CHAPTER 12

Veterinary Nutraceuticals, Pharmaceuticals and Vaccine

Amjad Islam Aqib^{1,*}, Muhammad Shoaib², Muhammad Aamir Naseer³, Saad Ahmad⁴, Mubashrah Mahmood⁵, Faisal Siddique⁶, Tean Zaheer⁷, Aisha Mahmood⁸ and Iqra Muzammil⁹

¹ Department of Medicine, Faculty of Veterinary Science, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, 63100, Pakistan

² Institute of Microbiology, Faculty of Veterinary Science, University of Agriculture, Faisalabad, 38000, Pakistan

³ Department of Clinical Medicine and Surgery, Faculty of Veterinary Science, University of Agriculture, Faisalabad, 38000, Pakistan

⁴ Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Lanzhou, China

⁵ Department of Theriogenology, Faculty of Veterinary Science, University of Agriculture, Faisalabad, 38000, Pakistan

⁶ Department of Microbiology, Faculty of Veterinary Science, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, 63100, Pakistan

⁷ Department of Parasitology, Faculty of Veterinary Science, University of Agriculture, Faisalabad, 38000, Pakistan

⁸ Department of Physiology, Faculty Of Veterinary And Animal Sciences, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

⁹ Department of Veterinary Medicine, Faculty of Veterinary Science, University of Veterinary and Animal Sciences, Lahore, 54000, Pakistan

Abstract: Animals have been utilized extensively as part and parcel of pharmaceutical and vaccine development. Many studies from animal models for human diseases have re-affirmed inventions in the field of medicine. Animal nutraceuticals of biological origin have marked exceptional promise by enhancing the production and performance of commercial animals. Transgenic animals have helped transform laboratory-scale developments into clinical applications. The nutraceutical potential of animal products is a fascinating area of research with considerable anti-microbial, anti-cancer, anti-inflammatory, anti-diabetic and neuroprotective functions. Vaccines in veterinary sciences have been revolutionized based on the efficacy demonstrated by animal models. Vaccines are being routinely used against bacteria, viruses and some parasites at commercial levels. Third-generation vaccines that were thought to be very expensive

* **Corresponding author Amjad Islam Aqib:** Department of Medicine, Faculty of Veterinary Science, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, 63100, Pakistan; Tel: +9237474583; E-mail: amjadislamaqib@cuvas.edu.pk

Muhammad Sarwar Khan (Ed)

All rights reserved-© 2021 Bentham Science Publishers

in the last century are now being commercially produced and marketed worldwide for animal health. Most recently, many avenues have opened that encourage the use of biologically derived pharmaceuticals and vaccine products. This chapter deals with a very comprehensive contrast of history and recent trends in veterinary pharmaceuticals and vaccines. It concludes that more research focus is required to come up with more efficient treatment and prophylactic approaches amidst mutating pathogens of concern.

Keywords: Animal peptides and proteins, Nutraceuticals, Passive immunization, Pharmaceuticals, Vaccines.

1. INTRODUCTION

Over the 300 years of the history of biomedical and pharmaceutical work, animals are of prime importance in regard to testing models as well as the source of pharmaceutical products [1]. It is an essential part of toxicological studies to utilize animal paradigms to explore the pharmaceutical pros and cons of the underlined products [2]. Animal carcass and its by-products have been used as a potent medicinally important biochemical for a long time. These biochemicals are highly labile to proteolytic enzymes, microbial as well as mal-handling degradation, which renders their quality and quantity. Market analyses showed that animal health pharmaceuticals has emerged as a progressive and proactive industry in world-leading forums [3]. Animal pharmaceuticals has a collection of nutrition, reproduction, and production-related entities; entitled in Chinese, herbal and modern medications [4]. After the down shock from Transmissible Bovine Spongiform Encephalopathy (TBSE), quality maintenance has become an optimistic point of concern in the animal pharmaceuticals and veterinary products market. Provision and critical analysis of the anatomical, biological, and geographical justification of animal products and by-products are of prime importance in the drug development industry. Reports from the Swiss Market showed 438 out of 655 pharmaceutical products of animal origin undergone the strict screening of TBSE [5]. Another study revealed that 530 out of 535 laboratory synthesized pharmaceutical products in the market are positive to at least one carcinogenic testing assay. Moreover, about half of the pharmaceutical ingredients used in Germany are reported to be of environmental relevance and are potent contaminants. This indicates the safety ranges of artificial products and empowers the concept of utilizing natural resources in this regard [6].

Pharmaceutical proteins of animal origin have been used since the 1920s, when insulin was extracted from the pig pancreas for human use. Later in the 1980s, this job was done using biotechnologically prepared recombinant microbes. In 2006, the pharmacologically active protein “antithrombin III” was approved as a medicinal product by European Medicinal Evaluation agencies. Other

pharmaceutically important proteins include human growth factors, hormones, coagulation factors, monoclonal antibodies, interferons, enzymes, and collagen [7].

2. VETERINARY ORIGIN NUTRACEUTICS

Milk peptides are proven excellent dietary supplements as well as potent pharmaceuticals. According to numerous studies, milk contains several biologically active peptides that can enhance antibacterial activity. These peptides have a variety of physiological functions, including metabolic, immunomodulatory, antibacterial, thrombolytic, and prebiotic/probiotic functions [8]. Alpha1-casein-derived peptides are the first antibacterial peptides to be effective against a wide variety of gram-positive bacteria, including *Staphylococcus aureus*. The N-terminal α 1-casein peptide can be used *in vitro* to counteract lactobacilli and gram-positive bacteria. It also provides effective protection against *Streptococcus pyogenes*, *Staphylococcus aureus*, and *Listeria monocytogenes* [9]. Therefore, according to the literature, these biologically active peptides change their biological function due to their ability to bind specific receptors to target cells and induce various biological reactions in the host organism, as shown in Table 1. Bovine casein can produce peptides such as SKVLPVPQK (β -CN; f168-176), YQKFPQY (α s2-CN; f89-95), LPYPYY (κ -CN; f56-61), LPQNIPPL (β -CN; f70). I will. -77), FLPYPYY (κ -CN; f55-61), and two novel angiotensin-converting enzyme (ACE) inhibitor peptides [10]. Compared to milk casein, milk casein contains more α -S2 and β casein than κ 180 casein. Alpha S2-casein consists of two main components and several secondary components with varying degrees of post-translational phosphorylation. Kappa-casein can inhibit toxin invasion and pathogenic adhesion to the cell wall and protect cells from infections mediated by *Porphyromonas gingivalis*, *Salmonella*, *Rhodococcus*, *Streptococcus mutans*. It is hydrolyzed by mineral binding peptide 1 and binds zinc and iron ions to form a soluble dialyzable complex. This product is best at removing 2,2-diphenyl-1-pyridhydrazino (DPPH), which strengthens the immune system [11].

Table 1. Therapeutic usage of milk constituents [11 - 19].

| Sr. No. | Milk Derived Bio-Active Constituents | Action Spectrum |
|---------|--------------------------------------|--|
| 1. | Opioid peptides | Agonist of opioid receptors |
| 2. | Angiotensin inhibitory peptides | Antihypertensive effect |
| 3. | Antimicrobial peptides | Bactericidal |
| 4. | Immunogenic casein peptides | Lymphocytic and macrophage proliferation |
| 5. | Antithrombotic peptides | Inhibit fibrin binding and platelets aggregation |

CHAPTER 13**Plant Molecular Pharming For Livestock And Poultry****Rimsha Riaz¹, Saher Qadeer¹, Faiz Ahmad Joyia¹, Ghulam Mustafa¹ and Muhammad Sarwar Khan^{1,*}**¹ *Center of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture, Faisalabad – 38040, Pakistan*

Abstract: Plants are exploited as bioreactors for the cost-effective production of pharmaceuticals, predominantly for the expression and accumulation of antigenic proteins, to be used as vaccines for livestock and poultry. Due to the high body mass of large animals and large population of poultry and other birds, a larger quantity of vaccines is needed continuously. It increases the production costs of vaccines for these animals. Under high biomass production ability, plants represent promising biofactory with added advantages of pathogen-free production of desired proteins in bulk quantities. Hence, plant-based transient, as well as stable expression systems, have been exceedingly applied to express immunogenic proteins. We have been using various plants like soybean and *Trifolium* to produce edible vaccines for poultry and livestock, respectively. Here we have reviewed various types of vaccines with a special focus on their plant-based expression with examples of Infectious Bursal Disease (IBD), New Castle Disease (ND), and Foot and Mouth Disease (FMD).

Keywords: Biopharming, Molecular pharming, IBD, ND, FMD, Vaccine, Edible vaccine, DNA vaccine, Subunit vaccine.

1. INTRODUCTION

Plants have been used for medicinal purposes since ancient times. More than 120 plant-derived drugs/pharmaceuticals have been approved for commercial utilization. Plant-derived pharmaceuticals include pain killers, wound healers, diagnostic reagents, antibiotics, therapeutic proteins, antimalarial and anticancer drugs [1]. These exogenous proteins are mostly produced as monoclonal antibodies, drugs, and vaccines not only to treat diseases but also to provide

* **Corresponding author Muhammad Sarwar Khan:** Center of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture, Faisalabad – 38040, Pakistan; E-mail: sarwarkhan_40@hotmail.com

additive nutrients. Plant molecular farming gained more importance after the production of insulin using a bacterial expression system in 1982 [2]. Since then, numerous medicinal products have been produced by using different expression systems, *i.e.*, mammalian cell lines, insect cell lines, and yeast cell lines. Compared to the conventionally produced pharmaceuticals, recombinant therapeutic proteins can be complex with an intricate mode of action. Owing to the involvement of complex biochemical pathways, their chemical synthesis is quite difficult and has numerous limitations so they must be produced in a living system to exploit the host cellular machinery for protein synthesis [3]. Each of the production systems has certain advantages and pitfalls regarding production cost, risks of contamination, post-translational modifications, downstream processing cost, regulatory and approval issues, *etc.*

Most of the commercial pharmaceuticals are produced through mammalian cell lines, yet the plant expression system has its significance [4]. Pioneering research on plant expression systems (plant-based pharmaceuticals) has proved its competitiveness for commercial applications. Compared to other production platforms, plants have several distinctive attributes to produce a wide variety of valuable pharmaceuticals. Various industrial enzymes, vaccine candidates, and monoclonal antibodies have been successfully expressed in plants because they are easy to scale up and do not require capital investment for infrastructure. They can be cultivated in a greenhouse or open fields, and as a result, the cost of production is very low. They are also free from human and animal pathogens; therefore, they are biosafe with limited chances of contamination [5]. Furthermore, plants can produce recombinant proteins with proper post-translational modifications. Hence, effective recombinant therapeutic proteins can be produced at the commercial level in a short period [6 - 8].

Elelyso[®] was the first recombinant therapeutic protein that was commercially produced in plants in 2012 and was approved for enzyme replacement therapy. Numerous plant species have been explored to produce various proteins of pharmaceutical importance. The most notable are: production of diagnostic reagent (avidin) in maize, commodity chemicals in rice, veterinary medicine in strawberry, and nutraceuticals in barley [9]. A large number of whole plant-produced pharmaceuticals are in pipeline for commercialization, *i.e.*, influenza vaccine is in 3rd phase of the trial. A large number of proteins including pharmaceuticals have been attempted to be produced through plant expression systems. This chapter highlights the use of plants as a valuable source for the production of biopharmaceuticals with special emphasis on the proteins of worth for livestock and poultry. Further, comparisons among different expression systems and transmission of diseases from animals to humans have also been discussed.

2. GLOBAL IMPORTANCE OF LIVESTOCK AND POULTRY SECTORS

Animal-derived food demand has drastically increased owing to the rapidly increasing population, increased income, and urbanization. The livestock species play a critical role not only to fulfill protein needs but also in the well-being of poor farmers, all over the world [10]. Besides meat and milk, several other products (animal fat, skin, hides, and horns) are used for domestic consumption as well as for the manufacture of various industrial products. Total world meat production has increased to 342.42 million tonnes where major contributors are poultry, pork, cow, buffalo, sheep, goat, camel, horse, and ducks. In 2018, approximately 302 million cattle, 479 million goats, 574 million sheep, 456 million turkeys, 1.5 billion pigs, and 69 billion chickens were killed or slaughtered to obtain meat. Likewise, milk production has increased to 800 million tonnes, but still, there is a continuous increase in the demand for animal protein and milk [11].

Compared with other sources of animal proteins, poultry meat has shown the fastest trend of growth during the last decades. During the last 50 years, the growth rate of poultry meat was 5%, that of beef was 1.5%, for pork it was 3.1%, and for small ruminants, it was 1.7% [12]. This growth trend is even higher in developing countries, particularly South East and East Asia (7.4%). The top-most producer of poultry meat is United States (20 million tons), followed by China (18 million tons), European Union (EU), and Brazil (13 million tons per annum). More than 23 billion poultry birds are present on the planet whereas efforts are in progress for its improvement through breeding and advanced molecular research. Poultry meat and eggs are the most common animal food, consumed all over the world. It is categorized as the most efficient sub-sector regarding protein provision and use of natural resources. Increased per capita consumption is a clear-cut indication of the importance of poultry. Egg consumption has increased from 4.55 kg to 8.92 kg whereas meat consumption has increased from 2.88 kg to 14.13 kg. Though the poultry sector has contributed a lot to ensure food security by providing proteins, energy, and essential nutrients to humans yet further efforts are direly needed to fulfill the ever-increasing demand for eggs and meat [13]. Further, it has widespread implications in the manufacture of non-food products which need to be explored and worked out. Thus, producing more from less without affecting the environment is the key to meet the sharply increasing demands of animal protein and its by-products.

SUBJECT INDEX

A

- Acid 136, 203, 235, 339
 nucleic 136, 203, 235
 polylactic 339
 Acquired Immunodeficiency 239
 Activity 31, 68, 76, 89, 100, 102, 109, 142,
 144, 196, 197, 276, 279, 288, 307, 309,
 325, 333
 antibacterial 197, 325
 antifungal 100
 antimicrobial 196
 antiviral 100, 333
 licensed vaccine 31
 proteolytic 276
 Acute 298, 301, 302, 303, 304, 305, 307, 309
 cardiac infarctions 298
 coronary syndrome (ACS) 303, 304, 307,
 309
 myocardial infarction (AMI) 301, 302, 303,
 304, 305
 Adaptive immune responses 2, 271
 Affinity 12, 137
 chromatography 12, 137
 column chromatography 137
 African horse sickness (AHS) 43, 170
 virus (AHSV) 43, 170
 Alkaline phosphatase (AP) 14, 215
 Alzheimer disease 169
 Anemia 126, 147, 333
 Angiogenesis 305, 333
 Angiotensin-converting enzyme (ACE) 313,
 325
 Anti-endopolygalacturonase monoclonal
 antibody 214
 Antigenic protein production 354
 Antigen-presenting cells (APCs) 2, 3, 11, 308,
 358
 Antihypertensive effect 325
 Anti-hypertensive inhibiting 102
 Anti-zearalenone monoclonal antibody 214
 Aortic stenosis 304
 Arabidopsis 90, 171, 175, 180, 272, 282, 283
 Arteriosclerosis disease 307
 Arthritis, rheumatoid 270, 328, 340
 Artificial 4, 45, 313
 bee colony (ABC) 313
 intelligence methods 4
 neural networks (ANNs) 45
 Assay 13, 14, 15, 17, 143, 198, 199, 204, 213,
 215, 324, 367
 chromatographic 198
 efficient detection 199
 enzyme-linked immunosorbent 13, 14, 198
 hemagglutination inhibition 367
 immunological 213
 linked immunosorbent 204
 Asthma 119, 330, 333, 334
 bronchial 330
 Asymptomatic hosts 200, 204
 Atherosclerosis 298, 306
 Atrial septic defects (ASD) 333
 Aujeszky's disease in swine 357
 Avian Influenza Virus (AIV) 170, 357, 372

B

- Bacillus* 6, 147, 172, 236, 272, 275
 anthracis 6, 147, 236, 272
 licheniformis 275
 thuringiensis 172
 Bacterial 120, 168
 cell-based processes 120
 lipoprotein 168
 Basic local alignment search tool (BLAST)
 49, 85, 89
 Bovine 275, 335, 338
 ephemeral fever 335
 respiratory disease 335
 retrovirus (BRV) 275
 viral diarrhea (BVD) 335, 338
 Brucellosis 43, 236, 334, 352, 353

Muhammad Sarwar Khan (Ed.)

All rights reserved-© 2021 Bentham Science Publishers

C

Cancer 40, 92, 147, 148, 165, 166, 237, 267, 269, 270, 273, 333, 336, 337, 339
 breast 92, 339
 gastric 92
 lung 92
 Cardiac 298, 300, 301, 302, 303, 304, 305, 306, 308, 313
 infarction 305, 306, 308
 injury 301
 myocytes 308
 myosin-binding protein 304
 troponins 298, 300, 302, 303, 304, 313
 Cauliflower mosaic virus (CMV) 7, 141, 278, 363, 366
 Cervical cancer 169, 239
Chenopodium quinoa 243, 366
 Chikungunya virus 43, 166, 235, 239, 244
 Chinese Hamster ovary (CHO) 331, 360
Chlamydia 6, 139
pneumoniae 6
trachomatis 139
 Cholera 11, 148, 168, 169, 170, 237, 271, 371
 toxin B (CTB) 11, 148, 168, 169, 170, 237, 271, 371
 vaccine 148
 Chromatography 133, 135, 136, 137
 anion exchange 137
 cation exchange 137
 Circular dichroism (CD) 12, 76
 Classical swine fever virus (CSFV) 170, 336, 372
Clostridium 139, 170, 237
botulinum 237
perfringens 170
tetani 139
 Coalition for epidemic preparedness
 innovations (CEPI) 235
 Coat protein (CP) 130, 243, 358
 Collagen 171, 174, 274, 307, 325, 330
 diseases 330
 interstitial membrane 307
 plant-derived 274
 protein 274
 Column chromatography 136
 Conformational epitope predictor (CEP) 8, 39, 48
 Congenital heart diseases (CHD) 298, 299
 Coronary artery disease (CAD) 301, 304, 307

Cosmetic industry 334
 Crimean-Congo hemorrhagic fever (CCHF)
 234, 244
 virus (CCHFV) 244, 245
 Cystic fibrosis 175, 271, 327, 328
 Cytotoxic T lymphocytes (CTLs) 2, 41

D

Deficiencies 310, 311, 328, 330, 353
 hereditary anti-thrombin 328
 metabolic 330
 Dengue virus 165, 239, 249
 Detection techniques 203, 204
 Diabetes mellitus 303, 333
 Direct transmission of pathogens 352
 Diseases 51, 121, 125, 234, 245, 267, 268, 269, 270, 272, 287, 288, 299, 305, 307, 308, 328, 330, 337, 340
 autoimmune 328
 cardiac 245, 307, 308
 cerebrovascular 299
 dermatologic 330
 ebola virus 234, 245
 hepatic 125
 life-threatening 51, 121, 267, 268, 269, 270, 287, 288
 metabolic 272, 337
 neurodegenerative 269, 340
 peripheral arterial 299
 peripheral artery 305
 Disorders 269, 330, 333, 334, 336
 autism spectral 333
 auto-immune 336
 digestive 334
 metabolic 269
 rheumatic 330
 DNA 11, 68, 212, 286, 339, 349, 357, 358
 based vaccines 11, 357
 engineered plant 286
 for gene transfection 339
 plasmid 358
 polymerases 68, 212
 vaccines 349, 357, 358
 Duckweed expression technology 277

E

Ebola virus disease (EVD) 234, 245

Echinococcus granulosus 6, 273
 Eco DNA Polymerase 68
 Electrocardiogram 300, 303
 Electrophoresis 15, 205
 Emerging infectious diseases (EIDs) 167, 226, 234, 235, 352
 Enzyme 204, 331, 332, 350
 hyaluronidase 332
 immunoassays 204
 replacement therapy (ERT) 331, 350

F

Fabry disease 175, 331
 Failures 298, 299, 300, 302, 303, 306, 312, 330
 cardiac 298, 299, 302, 306, 312, 330
 kidney 300, 303
 Fever, yellow 352, 357
 Fibrinolytic drug 175
 Fimbrial protein 335
 Flagellin protein 335
 FLAPs proteins 211
 Flavivirus 358
 Flow cytometry 17
 Fluorescent microscopy 286
 Follicular 237, 331
 lymphoma 237
 stimulating hormone (FSH) 331
 Food 45, 66, 67, 102, 200, 203, 227, 236, 275, 281, 282, 283, 284
 contamination 282, 283
 deficiency 236
 derived hypotensive peptides 102
 Foot and mouth disease (FMD) 169, 170, 271, 272, 334, 335, 349, 353, 354, 355, 368, 369
 Förster resonance energy transfer (FRET) 339
 Fungal mycotoxins 200
 Fusarium 198, 202, 207, 209, 216
 ear rot disease 202
 graminearum infections 207
 infections 198
 mycotoxigenesis 209, 216
 mycotoxins 216
 Fusion proteins 131, 206, 211, 270, 276, 280, 336, 367

G

Gastrointestinal infections 271
 Gaucher's disease 164, 228, 268, 283
 Genetically modified (GM) 45, 123, 126, 139, 267, 268, 269, 280, 284, 328, 329
 Genetic transformation technique 126
 Glucosylceramidase 331
 Glutamate dehydrogenase 68
 Glutathione reductase (GR) 280
 Gocher's disease 331
 Green fluorescent protein (GFP) 131

H

Hand-foot-mouth disease 240
 Heart 302, 303, 305, 312
 attack 302, 303, 312
 fibrosis 305
 Heart diseases 299, 300, 313, 333
 coronary 299, 300, 333
 Heart failure (HF) 300, 301, 302, 305, 306, 312, 313
 Heat stress 326
Helicobacter pylori 273
 Hemorrhagic 244, 355, 364
 fever 244
 septicemia 335, 364
 Henipaviral diseases 234
 Hepatitis C virus (HCV) 43, 170, 241, 337
 Herpes simplex virus 166, 241, 278
 Hidden Markov models (HMM) 45, 110
 Histophilosis 335
Histoplasma capsulatum 199
 Human 2, 170, 239, 282, 286
 leukocyte antigen (HLA) 2
 papillomavirus (HPV) 170, 239, 282, 286
 Hydatidosis 337
 Hydrophobic reaction 136, 137
 Hypersensitive reactions 45
 Hyperthermophiles 66
 Hypothyroidism 330

I

Immune epitope database (IEDB) 4, 7, 45, 48, 49
 Immune system 212, 337
 disorders 337

Subject Index

response maturity 212
Infections 33, 34, 35, 40, 181, 195, 198, 200, 201, 207, 208, 216, 244, 245, 246, 247, 248, 336, 353, 354, 355, 356, 363
antibiotic-resistant 40
fungal 195, 200, 201, 216
nosocomial 40
post-vaccination 248
rotavirus 353
smallpox 33
Infectious 246, 372
bronchitis virus 372
disorder 246
Infectious Bursal disease (IBD) 349, 364, 365
virus (IBDV) 15, 16, 365, 367
Inflammatory 298, 330
diseases 330
proteins 298
Influenza A virus (IAV) 242, 243, 246, 335

K

Kininogenase 331
Klebsiella pneumoniae 43

L

Lactoperoxidase 333
Lactoproteins 333
Lactuca sativa 169, 170, 237, 241, 243, 361
Lassa fever 234, 235
virus 235
Lateral 13, 16, 337
flow assays (LFAs) 13, 16
sclerosis 337
Leishmaniasis 238
Leptospirosis 43
Listeria monocytogenes 325
Lupus erythematosus 330

M

Major histocompatibility complex (MHC) 2, 9, 32, 38, 42, 45
Malaria 169, 230, 238, 327, 352
Malnutrition 236
Mammalian 12 2678,
processes 128
toxins 267

Frontiers in Protein and Peptide Sciences, Vol. 2 387

Marburg virus disease (MVD) 234, 243, 247
Mass spectrometry (MS) 12, 13, 16, 34, 72, 83, 91, 92, 99, 100, 205, 338
technologies 338
Mass vaccination 245
Mathematical modeling systems 51
Mayaro virus 43
Measles 32, 139, 272
Mechanisms 46, 86
hybrid 46
protein synthesis 86
Medicago sativa 138, 237, 369, 370
Meningococcal meningitis 34
Merozoite surface protein (MSP) 169, 271
Methicillin-resistant *S. aureus* (MRSA) 40
Monoclonal antibodies 124, 205, 206, 209, 213, 228, 229, 270, 325, 327, 349, 350, 354
Multi-epitope 11, 30, 42, 43, 44
peptide vaccine 43, 44
vaccine 11, 30, 42, 43
Multifunctional enzyme enniatin synthetase 197
Murine hepatitis virus 372
Mutagenesis 44, 66, 333
scanning 44
Mycobacterium tuberculosis 42, 169, 237, 337
Mycoplasma pneumonia 352
Mycotoxigenesis 200, 201
Mycotoxigenesis 207, 212, 216
Myocardial 298, 300, 301, 302, 303, 308, 312
hypertrophy 308
Infarction 300, 312
injury (MI) 298, 300, 302, 303
stress 298, 300, 301
Myocardiopathy 368
Myosin-binding protein 304

N

Natriuretic peptides (NPs) 246, 298, 301, 302, 335, 339
Necrosis 130, 303, 304
myocardial 303
myocardial infarction 304
Neisseria meningitidis 43
Neuraminidase 246
Newcastle disease (ND) 121, 147, 273, 334, 349, 354, 364, 367, 372
virus 273, 367

Nipah virus disease (NVD) 243, 248
 Nuclear magnetic resonance (NMR) 12, 44

O

Onychomycosis 198
 Orthologous proteins 76
Oryza sativa 138, 165, 172, 237, 238, 239,
 361, 362, 370
 Osteoporosis 327, 340
 Oxidative stress 312

P

Paget's disease 330
 Pancrelipase 332
 Panproteomics 85, 86, 92
 Pan-proteomics, prokaryotic 86
 Parkinson's disease 170, 340
 Pathogenicity island database (PAIDB) 37
 Peptide 43, 44, 197, 335
 synthetase 197
 vaccine 43, 44, 335
 Peptidoglycan recognition protein 326
 Peripheral 299, 338
 arterial disease (PAD) 299
 blood lymphocyte (PBL) 338
 Phagocytosis 305
 Plant transformation techniques 267, 284
Plasmodium falciparum 238
 Poliovirus 243
 Polymerase chain reaction (PCR) 67, 198,
 203, 204, 215
 Post-translational modifications (PTMs) 11,
 50, 51, 122, 124, 128, 350, 359, 360,
 361, 363
 Poultry vaccine 355
 Proline racemase 69
 Promastigote surface antigen (PSA) 238
 Protective antigen (PA) 236, 272
 Protein(s) 37, 84, 85, 100, 112, 131, 147
 disordered 112
 functional analysis 85
 green fluorescent 131
 hemagglutinin 147
 homologous analysis 85
 information resources (PIR) 37, 100
 quantification analysis 84, 85
 Proteolysis 4, 134, 279

Proteome(s) 34, 50, 81, 82, 83, 86, 87, 90, 91,
 92, 100
 comparisons 82, 86
 complexity 90
 functional 92
 Proteomic analysis 85, 86, 90, 273
 methods 85
 quantitative 86
 techniques 90
 Proteomics techniques 90

R

Rabies 33, 165, 228, 243, 334, 335, 352, 353
 Recombinant 34, 120, 124, 138, 176, 268, 274
 DNA technology 34, 120, 176, 268, 274
 end-proteases 138
 glucocerebrosidase 331
 technology 124
 Resources for protein 84, 85
 functional analysis 85
 homologous analysis 85
 quantification analysis 84, 85
 Respiratory 44, 165, 235, 241, 271
 syncytial virus 44, 165, 235, 241
 syndrome 271
 Reverse vaccinology (RV) 6, 30, 31, 34, 35,
 38, 39
 Rift Valley fever (RVF) 234, 243, 247
 virus (RVFV) 247
 Risk factors 302, 303, 310, 312
 cardiovascular 310
 traditional 303
 RNA 36, 177, 279, 280, 310, 362, 363
 interference (RNAi) 177, 279, 280, 362,
 363
 regarding non-coding 36
 Seq technique 310
 RVF disease 234

S

Saccharomyces 109, 122, 359
 cerevisiae 122, 359
 genome database (SGD) 109
Saccharomyces protein 109
Salmonella typhimurium 237
 Salmonellosis 352

Subject Index

- SARS-CoV 229, 248
 2 virus 229
 infection 248
Severe acute respiratory syndrome (SARS)
 47, 234, 248, 352, 353
Shock, septic 181
Single photon emission computed tomography
 (SPECT) 340
Somatotropins 125, 128
Staphylococcus 6, 34, 40, 43, 86, 170, 325
 aureus 34, 40, 43, 325
 agalactiae 86
 mutans 170, 325
 pneumonia 6
Swine influenza virus 243
Syndrome 249, 303, 353
 acute coronary 303
 thrombocytopenia 353
- T**
- Technologies 328, 366
 gene recombination 328
 transplastomic 366
Thermophilic enzymes 67, 70
Thermostable 71, 72
 haloalkane dehalogenase 72
 laminarinase 71
Tobacco 130, 141, 142, 179, 274, 286, 363
 etches virus (TEV) 363
 expression system 274, 363
 mosaic virus (TMV) 130, 141, 142, 179,
 286, 363
Total soluble proteins (TSP) 139, 140, 142,
 143, 148, 165, 166, 170, 171, 172, 177,
 284, 369, 370, 371
Toxins, tetanus 33
Toxoplasma gondii 44, 169, 238
Toxoplasmosis 238, 352
Transformation 32, 176, 179, 284, 369, 370
 of vaccinology 32
 process 176, 179
 strategy 369, 370
 systems 284
Transforming angiotensin enzyme 104
Transgenic 125, 126, 162, 163, 164, 167, 168,
 180, 181, 208, 236, 237, 238, 280, 281,
 283, 284, 364, 367
 plants 125, 126, 162, 163, 164, 168, 180,
 181, 208, 236, 237, 238, 280, 281, 283

Frontiers in Protein and Peptide Sciences, Vol. 2 389

- potato 367
 technology 168, 364
 tomatoes 284
 DNA introduction 176
Transmissible bovine spongiform
 encephalopathy (TBSE) 324
Trypanosoma cruzi 44
Trypanosomiasis 44
Tuberculosis 33, 139, 237, 333, 352, 353
Tumor-specific antigens (TSAs) 41
- V**
- Vaccine(s) 11, 40, 101, 121, 141, 147, 149,
 267, 335, 358
 multi-epitope-based 40
 peptide-based 11
 production 101, 121, 141, 147, 149, 267,
 335, 358
Vancomycin 40
Ventricular dysfunction 305
Veterinary vaccines 334, 353, 372
Vibrio cholerae 43, 168
Viral protein 51, 356, 358, 365
Viral vaccines 356
 engineered 357
 killed 356
 live 355, 356
Virus 12, 13, 15, 31, 42, 130, 180, 181, 229,
 240, 243, 277, 285, 286, 358
 induced gene silencing (VIGS) 180
 infection method 130, 285, 286
 like particles (VLPs) 12, 13, 31, 42, 181,
 229, 240, 243, 277, 358
 neutralization test (VNT) 13, 15
VLPs-based vaccines 229
- W**
- Waals interactions 67
Western blot analysis 286
West Nile virus (WNV) 142, 165, 243, 249,
 357, 358
White spot syndrome virus (WSSV) 43
- X**
- X-ray 4, 6, 7, 12, 44
 crystallography 4, 6, 7, 12

diffraction 44
Xylanase 170, 171
 tobacco chloroplast 170, 171
Xylarioides endoantigens 215

Y

Yeast expression systems 122, 361

Z

Zika virus 44, 166, 234, 244, 249
 disease 234, 244, 249
ZIKV vaccine 249
Zinc-dependent endopeptidase 307



Muhammad Sarwar Khan

Muhammad Sarwar Khan has an established academic career in Plant Molecular Biology, Biopharming, and Education. He started his career as a graduate student researching nutritious plants' biotechnology and afterwards, he earned his Ph.D. in Plant Molecular Biology specializing in Chloroplast Biotechnology from the University of Cambridge, UK. Dr. Khan was awarded a prestigious postdoctoral fellowship by The Rockefeller Foundation for researching at the Waksman Institute of Microbiology, Rutgers, the State University of New Jersey. His findings—research of first-of-its-kind—was published in *Nature Biotechnology*. Dr. Khan was appointed as National Coordinator to intermediate level students for participation in the International Biology Olympiads. He served as the founding Group Leader of Chloroplast Biotechnology and Biopharming Group, then as founding head of the Biotech Interdisciplinary Division (BID) at NIBGE, and is currently serving as Professor and Director of the Center of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture, Faisalabad, Pakistan. He has served as Director General of the Social Safety Net Program of the Government of Pakistan.

Dr. Khan has supervised more than 100 Ph.D. scholars, MPhil students, and researchers who are now serving at national and international levels in various research institutes and universities. He has vastly published in high-impact journals and is the author of several book chapters and books. His current research interests include the development of plant-based cost-effective therapeutics and edible vaccines for animals. Dr. Khan has received prestigious awards, including the President's Medal for Technology, a Gold Medal in Agriculture from the Pakistan Academy of Sciences, a Performance Gold Medal by PAEC, the Biotechnologist Award by the National Commission of Biotechnology, and the Best University Teacher Award by the Higher Education Commission of Pakistan. He is also a fellow of the Cambridge Commonwealth Society, the Cambridge Philosophical Society, and a member of the International Association for Plant Biotechnology. Currently, he is serving as Editor/Guest Editor on several international research journals and books, being published by publishers like *Springer*, *Taylor & Francis*, *Bentham*, and *IntechOpen*.